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ABSTRACT 
 Pancreatic cancer is a devastating disease with a 5-year survival rate of less than 
6%. This poor outcome is heavily associated with the resistance of pancreatic tumors to 
chemotherapy and radiation therapy. The profound heterogeneity of pancreatic tumors is 
speculated to be one key reason for this intense resistance. To improve treatment outcome, 
it is crucial to evaluate the characteristics of pancreatic adenocarcinoma for each patient 
and to select or adapt tumor-specific therapy accordingly. Over the past ten years, evidence 
has pointed to the importance of circulating tumor cells (CTCs) in the spread of cancer 
through the metastatic process. These cells are shed by the primary tumor into the 
circulation and are now known to be key players in metastasis.  CTCs are believed to be a 
good surrogate biomarker for not only prognosis, but also for cancer detection and 
development of personalized treatment.  
This thesis outlines the use of a microfluidic device that allows for the isolation, 
expansion, and characterization of pancreatic CTCs. This device, named the Labyrinth, 
allows for the label free isolation of CTCs at a high throughput of 2.5mL/min, offering a 
biomarker independent CTC characterization platform to study heterogeneity among CTC 
subpopulations in pancreatic cancer. This Labyrinth allows for a high CTC recovery of 
92%, while having a WBC removal of 89%.  
The Labyrinth technology was used to investigate the use of CTCs for clinical 
prognosis. This was performed through a clinical study, where CTCs were isolated and 
enumerated for over 150 treatment naïve patient samples. CTC counts were then correlated 
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with treatment efficacy (surgery, chemotherapy or radiotherapy). Our results show for all 
treatment options there is a statistically significant decrease in CTC counts. Lastly, a trend 
was observed between the decrease of CTC count and higher overall survival among all 
treatment options.  
The employment of the Labyrinth for heterogeneity studies was then explored in this 
thesis. CTCs isolated from pancreatic cancer patients were monitored for markers 
associated with the cancer EMT cell population including CK, CD24, and CD90. We found 
that there were cells that were CK+, which were then characterized as CTCs, that also had 
CSC markers associated with them in most cases. Tissue analysis (IHC) from one of the 
patients showed the existence of this CTC subpopulation close to the tumor vasculature, 
suggesting their aggressiveness and ability to travel to the bloodstream to invade other 
organs. 
This thesis also describes in vitro and in vivo characterization performed on 
expanded CTCs. CTCs were isolated from ten pancreatic cancer patients with locally 
advanced disease using the Labyrinth and expanded in vitro for over 30 days. Expansion 
of CTCs was successfully achieved for 3 of the samples, giving a 30% success rate. CTC 
cultures were then characterized in both 2D (adherent) and 3D (spheroid) in vitro 
conditions. Furthermore, an in vivo study model (NOD SCID mice) was created, being the 
first ever pancreatic CDX model. This model displayed metastasis across several organs 
after only 3 weeks of CTC injection.   
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CTCs could serve as a potential avenue for a non-invasive alternative to diagnosing 
and treating pancreatic cancer and thereupon preventing the development of the disease. 
The isolation and expansion of CTCs, the heterogeneous population of cells that promote 
metastasis, can provide meaningful information to elucidate the process of pancreatic 
tumorigenesis to preempt its fatal result. 
 1 
CHAPTER 1. CIRCULATING TUMOR CELLS (CTCs) IN PANCREATIC 




The study of circulating tumor cells (CTCs) has been made possible by many 
technological advances in its isolation. Their isolation has seen many fronts, but each 
technology brings forth a new set of challenges to overcome. Microfluidics has been a key 
player in the capture of CTCs and their downstream analysis, with the aim of shedding 
light into their clinical application in cancer and metastasis. Researchers have taken 
diverging paths to isolate such cells from blood, ranging from affinity-based isolation 
targeting surface antigens expressed on CTCs, to label free isolations taking advantage of 
the size differences between CTCs and other blood cells. For both major groups, many 
microfluidic technologies have reported high sensitivity and specificity for capturing 
CTCs. However, the question remains as to the superiority among these two isolation 
techniques, specifically to identify different CTC populations. This chapter highlights the 
key aspects of affinity and label free microfluidic CTC technologies, and discusses which 
of these two would be the highest benefactor for the study of CTCs. 
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1.2 Pancreatic Cancer  
Pancreatic cancer is the fourth leading cause of cancer death in the United States. 
The overall 5-year survival rate among patients with pancreatic cancer is only 6%. This 
year, an estimated 46,420 new cases and 39,590 deaths from pancreatic cancer are expected 
to occur in the United State1. For all stages combined, the 1- and 5-year relative survival 
rates of pancreatic cancer are 27% and 6%, respectively. Surgery, chemotherapy, and 
radiation therapy are treatment options for pancreatic cancer patients. Even for these 20% 
patients with a tumor that has been surgically removed, the 5-year survival is about 20% 
to 25%. Although no evidence of metastatic is observed at the time of diagnosis, the median 
overall survival of those patients ranges only from 9 to 10 months 2.  
The poor outcome of pancreatic cancer treatment could partly be due to the resistance 
of pancreatic tumors to chemotherapy and radiation therapy3. Even if pancreatic tumors 
initially respond to treatment, they will eventually become resistant to the conventionally 
used agents. The profound heterogeneity and ongoing genetic instability of pancreatic 
tumors is speculated to be the key reason for this intense resistance. To improve treatment 
outcome, it is crucial to evaluate the characteristics of pancreatic adenocarcinoma for each 
patient and to select or adapt personalized tumor-specific therapy accordingly. Early 
identification of treatment response would provide valuable information for clinicians to 






   
3 
1.3 Circulating Tumor Cells (CTCs) 
Emerging evidence has pointed to the importance of circulating tumor cells (CTCs) 
in the spread of cancers 4. Circulating tumor cells (CTCs), suspected of being precursors 
of metastasis 5 have been in the spotlight as a liquid biopsy 6-9 and are being investigated 
as surrogate biomarkers for clinical trials 10-12. These are cells shed by a primary tumor into 
the blood circulation, and can potentially form secondary tumors en route (Figure 1.1) 13. 
Being intermediaries between the primary and metastatic tumors, they offer insights into 
both; additionally, they can reveal key aspects of the metastatic cascade. Indeed, there have 
been studies showing that CTCs have distinct identities, consisting of a heterogeneous mix 
of populations similar to both the primary tumor and the metastatic tumor 14-17. CTCs can 
be detected from the peripheral blood of patients and hold the promise of being a real-time 
biomarker for cancer detection and management 18. The utility of CTCs as a predictive and 
prognostic marker has been explored in various cancers like breast cancer, prostate cancer, 
liver cancer and colorectal cancer 19-22. For example, in patients with metastatic breast 
cancer, the number of CTCs before and during treatment is an independent predictor of 
progression free and overall survival 21,23. Nagrath et al. surveyed patients from different 
cancers in advanced stages over their treatment course and showed that changes in CTC 
numbers could predict changes in the tumor burden 24. Elevated CTC numbers during 
treatment have also been shown to be associated with disease progression 23,25. 
Furthermore, it is possible to monitor treatment resistant mutations and telomerase activity 
in CTCs, thereby demonstrating their clinical utility in therapeutic monitoring 26,27. 
The current gold standard for CTC isolation is the CellSearch (Veridex, USA) 
system, which is the only FDA approved system for CTC detection 22.  This test separates 
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epithelial cells using magnetic beads functionalized with antibodies against the epithelial 
cell adhesion molecule (EpCAM) 28. Using the CellSearch system it has been shown that 
CTCs have prognostic utility in breast, prostate and colon cancers 22. However, there is 
considerable cell loss (~20-40%) caused by the inability of the  platform to detect cancer 
cells with a reduced EpCAM expression, such as those that have gone through or are in the 
process of going through epithelial to mesenchymal transition (EMT) 29,30. Currently, CTC 
studies are geared toward finding genetic signatures that could guide treatment decisions 
31. 
The major challenge toward accomplishing more with these entities lies in their 
rarity; CTCs are detected at a frequency of tens among billions of blood cells 32,33. The vast 
majority of the background cells (blood cells) contribute to not only challenges in enriching 
for the target cells (CTCs), but purity issues during downstream molecular analyses 4. 
Attempts at increasing CTC concentrations by expanding them after isolation are hardened 
by viability issues 33. Hence, the key aspects of any CTC isolation technology should be a 
high recovery rate without compromising on purity and viability 33. A plethora of 
microfluidic technologies have risen to these challenges with promising results. With their 
help, scientists are now analyzing complex fluids such as blood in vitro, as a means to 
investigating non-invasive alternatives for cancer detection, patient prognosis and 
therapeutic monitoring 18. 
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1.4 Microfluidic Technologies for CTC Isolation 
Microfluidic devices have had a major impact on the field of CTC research 34. Such 
efforts have been facilitated by the automation of labor-intensive experimental processes 
involved in isolating and characterizing CTCs. Consequently, the microfluidic field has 
been gaining pace especially in the handling of rare cells 33,35. Different materials ranging 
from traditional silicon and glass to elastomers have been used for making these devices. 
The use of poly-dimethylsiloxane (PDMS), an elastomer, has made rapid prototyping an 
easy and preferred method, leading to widespread use of microfluidic technologies for 
investigating CTCs 32,36. Their smaller dimensions allow precise manipulation of fluid flow 
in the devices, translating to better control over the cells. The smaller volumes also demand 
lesser reagents 4. Microfluidics for CTC isolation gained popularity with the reporting of 
the CTC-chip 24. Over the years, many similar and innovative microfluidic platforms have 
come up, each exploiting specific properties of CTCs to separate them from blood cells. 
The different properties may be biological such as target antigens, or physical such as size, 
Figure 1.1 Circulating Tumor Cells (CTCs) 
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density, deformity 32,37. This review compares the two most widely-used methodologies, 
namely affinity-based (biological) and size-based (physical) techniques of CTC isolation. 
Microfluidic technologies are mainly categorized by their exploitation of CTCs’ 
distinctive (i) biochemical properties or (ii) biophysical properties. The former is based on 
the expression of cell surface markers, while the latter includes size, deformability, density, 
and electric charge 38.  For either of these strategies, it is imperative that developing an 
optimal CTC isolation method meet the following criteria: (i) high recovery, (ii) high purity 
of CTCs by removal of contaminating blood cells, and (iii) high system throughput to 
ensure handling of large sample volumes as expected for clinical settings 33. Capture or 
retrieval of CTCs is followed by identification by immunocytochemical staining 
demonstrating positive signals for Cytokeratin(s) and the nuclear stain DAPI (4’,6-
diamidino-2-phenylindole), with the absence of the leukocyte marker CD45 24. Although 
there are multiple methods in each category of isolation, this chapter will focus on two of 
the most prevalent methods for CTC isolation- affinity, and size based or label free 
isolation (Figure 1.2). Here, new progress and emerging technologies are highlighted for 
each isolation method. Furthermore, the advantages and disadvantages based on their 
downstream applications for studying subpopulations and heterogeneity, genomic 




Figure 1.2 Strategies for CTC isolation 
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1.5 Immunoafinity Based Technologies  
Affinity-based isolation, the main principle of technologies such as CellSearch and 
the CTC-chip 24, make use of the affinity of an antigen to its corresponding antibody. 
Antigens or surface markers present on the membrane of CTCs are targeted by specific 
antibodies that can be immobilized onto a solid surface 39. The antigens (and hence the 
cell) can grab on to the target antibodies under ideal conditions of affinity-binding. The 
bound cells can then be separated and/or identified for further assays, depending on their 
method of capture. The commonly used antigen for CTC capture is the Epithelial Cell 
Adhesion Molecule (EpCAM), and is considered to be expressed by epithelial cancers 18. 
While recent findings have brought into question the utility of EpCAM in identifying the 
aggressors 40, it still remains the most widely adopted choice of capture antibodies. 
Combinations of antibodies are also being employed to widen the capture net 41.  
The first immuno-capture microfluidic technology for CTCs, the CTC-chip 24 
consists of a series of 100 µm tall microposts coated with antibodies against EpCAM, 
which can interrogate whole blood for capturing CTCs expressing the antigen. The novelty 
of this technology lay in its ability to capture CTCs from whole blood with high sensitivity 
and viability 24. Following this, a number of technologies with varying degrees of 
sensitivity and purity were developed. The high-throughput microsampling unit (HTMSU) 
42, Cell Enrichment and Extraction (CEE) channel 43, Herringbone HB-chip 36, the graphene 
oxide chip 44, all performing EpCAM-based CTC capture, improved upon the above 
parameters. The NanoVelcro CTC chip, another recently developed immuno-capture 
device, makes use of nano-sized structures coated with EpCAM for CTC capture 45,46. 
Other nanomaterial based devices for CTC interrogation include the incorporation of 
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carbon nanotubes (CNTs), the porous nature of which provides a high surface area for cell 
interaction 47,48, and the use of TiO2 nanofibres (TINFs) produced by electrospinning 
techniques for anti-EpCAM capture of CTCs 49. The GEDI chip developed in 2010 50  has 
a similar approach and enabled CTC isolation with an antibody against prostate specific 
membrane antigen (PSMA). They showed an improved purity over the CTC-chip and also 
opened the arena for achieving CTC capture with antibodies other than EpCAM. Different 
antibodies or antibody cocktails have since been explored to capture different populations 
that may have been otherwise missed. Galletti et al. demonstrated the use of anti-Her2 for 
studying CTCs from breast and gastric cancer 51. Yu et al. used a mixture of EpCAM, 
EGFR and Her2 to capture CTCs from breast cancer 15. Pecot et al. used an interesting 
approach wherein the cells are tagged with a cocktail of antibodies, followed by capture by 
functionalized microchannels 41,43. Aptamers, which can be synthesized to specifically 
recognize target molecules on the surface of cells, have also been incorporated for CTC 
capture 52. An example of a microfluidic aptamer-based affinity capture device was 
demonstrated by Sheng et al. for capture of colorectal CTCs from whole blood 52. 
Immuno-magnetic capture is also a popular method of affinity isolation wherein 
magnetic beads coated with antibodies are made to bind to cells in order to separate CTCs 
from WBCs 4. MACS (magnetic activated cell sorter) is one such technology, that operates 
by separating cells bound to magnetic beads through a target antibody followed by 
purification under a magnetic field 53. Magnetic nanoparticles are also used to label cancer 
cells through anti-EpCAM to separate them from blood cells with high efficiency at a high 
flow rate of 10 ml hr-1 54. Another novel immunological approach was developed by Shi et 
al. in which microbubbles enveloped with anti-EpCAM were used for CTC isolation 46.  
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Affinity-based capture also holds negative selection under its umbrella, in which 
the target cells are made to pass through while leukocytes (WBCs) are targeted by 
antibodies against CD45 55,56, and/or CD15 56. The advantage of negative selection lies in 
its capability of isolating CTCs that may or may not express epithelial markers 56. This 
approach has been used in the CTC-iChip 56, and by Wu et al. 57. Casavant et al. used 
magnetic beads coated with anti-CD45 as a means of depleting white blood cells as a 
precursor to CTC enrichment 55.  
Recently, the limitation of throughput for immuno-affinity isolation of CTCs has 
been addressed by several devices operating at high flow rates. Of note are the 
demonstrations of the CTC-iChip 56 which is a combination of affinity and size-based 
isolation, an integrated high-throughput device by Liu et al. 58, immunomagnetic isolation 
at 10 ml hr-1 54, and the OncoBean Chip, a purely affinity isolation device operating at 10 
ml hr-1 developed in our lab 59. An in-vivo CTC detection technology, the GILUPI 
CellCollector, employing anti-EpCAM to capture CTCs in venous blood flow is also an 
example of a system that demonstrates CTC isolation even under high physiological shear 
stresses (20 ml min-1) present in the circulation 60. 
1.5.1 Advantages of immune-affinity based approaches 
CTC enumeration, albeit a very important part of CTC studies, is only one aspect 
of the clinical utility of these cells. And while CTC numbers have been correlated to 
prognosis 22, characterization of these cells is still an unmet and essential demand. With 
numerous technologies for CTC enrichment and enumeration in development, studies are 
now shifting gear toward addressing what these cells are capable of. With this in mind, a 
number of recent findings have been published showing CTCs’ ability to metastasize 61, 
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their tumor forming potential 15,62, their potential utility as agents showing drug response 
15 and their clonal heterogeneity 16. Baccelli et al. showed that CTCs are a diverse pool of 
cells, and may contain a certain population of metastasis initiating cells (MICs) which 
would be the aggressive cells 61.  
Because of the principle of capture, affinity-based isolation offers very high specificity of 
the recovered CTCs since the target CTCs are validated by the capture antigen in addition 
to identification by immunostaining procedures. The method also enables recovery of an 
assorted pool of CTCs, regardless of morphological considerations such as size. Whilst 
many size-based technologies may capture CTCs with high yields, the wide variability of 
CTC sizes previously reported 13,32,63 makes the smaller CTCs highly probable to be missed 
in size based techniques which are usually biased towards the larger cells. Affinity-based 
methods can indiscriminately capture such populations, and are also capable of doing the 
same without the need for preprocessing steps such as dilution or red blood cell lysis, 
invariably required by physical separation techniques 63. The specificity also allows for 
better downstream analysis which may have clinical utility. One such application was 
demonstrated by Maheswaran et al. who performed downstream sequencing studies on 
CTCs captured on an affinity platform (the CTC-chip) from lung cancer patients 26. 
Affinity capture also allows high purity of the recovered CTCs 50. Since these cells are rare, 
any downstream applications are dictated by the accompaniment of contaminating blood 
cells. The specificity of CTC capture by affinity techniques is also reflected in the retained 
background cells. The targeted capture not only allows for low non-specific retention but 
also washes away most red blood cells, eliminating the need for red blood cell lysis as a 
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precursor to blood analysis. The highly specific and pure CTC yield facilitated by immuno-
capture combined with the viability is also conducive to CTC culture and expansion 64. 
In order to efficiently study the diverse properties of CTCs, their isolation needs to 
be tailor-made to answer the relevant biological questions. Immuno-affinity offers a 
beautiful platform for this purpose as antibody-based capture techniques can be customized 
to target different subpopulations of CTCs.  A combination of antibodies consisting of the 
traditional anti-EpCAM with another marker, or successive captures with the respective 
individual antibodies can yield the desired populations 41,65. For instance, Riethdorf et al. 
utilized HER2 as a target agent to identify CTCs among patients undergoing neoadjuvant 
treatment for a HER2 inhibitor 11. Pecot et al. used an interesting cocktail of antibodies to 
target both epithelial cells and potential CTCs undergoing epithelial-mesenchymal 
transition (EMT) 41. Affinity-based capture techniques are thus widely capable of specific 
targeting of cell subpopulations, an area requiring deeper attention as more and more 
studies illuminate tumor cell heterogeneity 17. 
Affinity based methods also offer high utility with respect to capturing rare events 
such as CTC clusters 4,16. These clusters may sometimes be larger than the detection range 
of physical separation techniques and/or may clog the channels 66. CTC clusters are 
believed to have more metastasizing capability than single cells in the circulation 16,67. 
Larger clusters containing a heterogeneous mix of cells may also be captured if some of 
the cells in the cluster express the target antigen, thereby achieving capture of potentially 
“unfamiliar” populations using “known” targets. Furthermore, the generally lower shear 
experienced by cells in immuno-affinity capture 59 also enables collection of CTCs that are 
possibly circulating in conjunction with platelets. Platelets are believed to be implicated in 
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metastasis and platelet-enveloped CTCs may be important in disease progression as they 
are able to evade immune surveillance 16,68-70. 
1.5.2 Disadvantages of affinity-based approaches 
Traditionally preferred for CTC isolation 18, affinity methods have validated their 
utility in a number of CTC analyses studies. However, they suffer from a few limitations. 
Throughput is a major concern with antibody-based CTC recovery chips such as the CTC-
chip and HB-chip 56. This is due to the limited shear conditions under which affinity 
binding occurs 59. Microfluidic flow-based affinity capture requires optimal velocity and 
shear conditions for antibody-antigen binding 24,39. A very high shear may disrupt any 
bonds if formed, while a very low shear is conducive to non-specific cell binding 59. An 
optimal binding condition would provide adequate capture of target cells, with minimal 
amount of blood cells retained; in other words, a high efficiency with minimal 
contamination. These optimal conditions limit the velocity of flow during capture. The 
CTC-chip and its successors operating on similar principles therefore had an operating flow 
rate of 1-3 ml hr-1 59. In the CTC-chip itself, increasing the flow rate from 1 to 3 ml hr-1 
diminished the capture efficiency 24. This limits the blood volume that can be analyzed due 
to the time constraints it places on the experiments. Of late, a number of technologies have 
overcome the throughput limitation by introducing novel designs to circumvent the issue 
of optimal binding conditions 59.  
Epithelial-to-mesenchymal (EMT) transition, a process in which cells lose their 
epithelial characteristics and become more mesenchymal, is believed to be an important 
process hampering the study of CTCs on the basis of EpCAM alone 13. As these cells 
undergo the change, their EpCAM expression decreases, and they may be missed by 
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EpCAM targeted capture 13,71. These EMT-undergoing cells are believed to be important 
players in metastasis 71 and may be able to provide useful information about the 
dissemination of tumor cells 13. Combinations of antibodies are therefore being employed 
to capture not only epithelial cells, but also the mesenchymal ones 41. 
Many microfluidic affinity based technologies employ surface modifications for antibody 
conjugation and immobilization 24. This poses problems as many of the bonds are 
irreversible and cannot be easily degraded and/or may affect the viability of these rare cells 
themselves in the process 72. Subsequent assays such as single cell analysis and CTC 
derived xenografts may not be feasible in such cases due to cell release difficulties 72 . 
Many genetic analyses performed on CTCs thus depend on nucleic acid extraction from 
the pool of cells captured on these devices, which may create background noise as the 
captured populations contain impurities such as blood cells 4.  
1.6 Biomarker independent technologies for the isolation of CTCs 
The use of physical properties allows a label-free isolation, aimed to overcome 
biased cell selection using biological-based separation methods. This approach allows the 
isolation of intact cells without stressing their plasma membrane through antibody binding, 
which is a vital aspect for further downstream characterization of CTCs. This method tends 
to exploit the size differences among CTCs and other blood components. More specifically, 
CTCs have been shown to have a diameter of 13 to 25 µm in diameter 35, larger than the 
rest of the blood cells such as leukocytes with diameter ranges from 8 to 11µm  73, and red 
blood cells (RBCs) with diameters in the range of 5–9 µm 74.  Label-free approaches can 
be classified into three main categories- filtration, hydrodynamic chromatography, and 
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dielectrophoresis (DEP). In addition, other novel methods exploiting the physical 
properties of CTCs including acoustic separation have also been recently developed 75-77. 
Compared to immuno-affinity based approaches, the biomarker independent CTC 
isolation technologies are still evolving. While many of these have been optimized with 
cancer cell lines, few have been validated with clinical specimens. The use of cancer cell 
lines as a CTC model makes an ideal model for the optimization of a new technology. 
However, cell lines do not represent the heterogeneous morphology found in clinical 
specimens 78. Some subpopulations of CTCs will indeed be more deformable and smaller 
than cancer cell lines. Therefore, using cell lines to optimize new technologies may not 
serve as a true test of efficiency as their clinical utility will only be determined by testing 
clinical samples 79. Here, the recent label free microfluidic technologies that have been (i) 
characterized using cancer cell lines and (ii) clinically proven to work by isolating CTCs 
from patient samples over the past 5 years are summarized.  
Filtration Methods 
Membrane-based filtration is one of the first methods used for isolating CTCs, 
being a relatively straightforward and low cost technique. This method captures target cells 
using constrictions based on cell size and deformability 79. Most of the reported membranes 
have pore sizes around 7–8  µm diameter, with few reporting on membranes with pore size 
diameters up to 11  µm 80. Vona et al. proposed ISET (Isolation by Size of Epithelial Tumor 
Cells), a commercially available technology that uses a polycarbonate membrane-filter 81. 
This is a filtration method that uses 8 µm cylindrical pores to capture CTCs. However, its 
large variability in CTC capture efficiency and low purity caused by membrane clogging 
left opportunities for further improvement. Integrating microfabricated filtration 
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membranes into microfluidic devices has since emerged as an optimized approach for CTC 
separation. Materials such as polycarbonate 82-84, parylene-C 85-87, nickel 88 and silicon 89 
have demonstrated to provide the appropriate membrane surface area and porosity to 
enhance CTC capture.  
In 2010, Lin et al. published one of the first label free methods to be tested using 
clinical samples 86. With a total of 57 human samples from various cancer types, this 
parylene membrane microfilter identified CTCs in 51 out of 57 patients compared to only 
26 patients with the CellSearch method. Tan et al. published a label free biochip that uses 
physical structures or pillars to trap single cells without having cell buildup 90. Lim et al. 
developed a silicon microsieve that contains a  dense array of pores to isolate CTCs at a 
flow rate of 1 ml min-189. Zhou et al. designed a device that aims for the filter-based capture 
of viable cells with the use of a design that incorporates a low mechanical stress, termed 
the separable bilayer (SB) microfilter 91. The high viability of enriched CTCs using the SB 
microfilter allows for functional analysis and on-chip expansion of CTCs, further discussed 
in the next section of this review.  
Hydrodynamic Methods  
Hydrodynamic based approaches have shown the highest throughput capability 80. 
Recently, inertial migration of particles has been introduced and applied in various studies 
to achieve high throughput separation based on particle size 92. Briefly, the particles 
migrate and are focused in microchannels due to the equilibrium of two inertial lift forces 
which act on the particles in opposite directions- shear gradient lift force and wall lift force 
92. Some other technologies exploit a secondary flow called Dean flow that takes place in 
curvilinear channels 93. In addition, hydrophoresis is another approach that makes use of 
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rotational flow for separating particles based on size 94. Another approach, termed 
deterministic lateral displacement (DLD), in which microposts are strategically placed to 
divide the flow into several laminar streams,  are also  used for separation of  CTCs from 
blood cells 95. Regardless of the type of hydrodynamic based technologies, the goal is to 
impart different flow velocities based on cell size differences to separate the target cells 
with high efficiency. Lee et al. developed a lab-on-a disc platform that utilizes centrifugal 
force to rapidly transfer unprocessed whole blood samples from one chamber to another 96. 
The selective isolation of CTCs was achieved through the use of a commercially available 
track-etched polycarbonate membrane filter on a lab-on-a-disc system. Hou et al. 
developed a spiral microchannel for separation of CTCs using centrifugal forces, a 
principle known as Dean Flow Fractionation 63. Using this device, they were able to detect 
a subpopulation of CTCs that were positive for CD133, a phenotypic marker characteristic 
of stem-like behavior in lung cancer cells 97. Furthermore, this device was the first inertial 
device to demonstrate the capacity to process blood samples with a high hematocrit. Our 
group also demonstrated theoretical investigation of inertial separation of CTCs using 
cascaded spiral microfluidics 98. Sollier et al. developed the Vortex Chip, which uses 
micro-scale vortices and inertial focusing to isolate CTCs 99. Hyun et al. developed a 
parallel multi-orifice flow fractionation (p-MOFF) device in which contraction/expansion 
microchannels were placed in a parallel configuration for CTC separation 100. This device 
was shown to use inertial forces to isolate CTCs from 24 breast cancer patients at a high 
throughput 100. Warkiani et al. developed the trapezoid chip, which uses a trapezoidal 
design and exploits Dean forces and lift forces to isolate CTCs 101. More recently, Warkiani 
et al. reported an ultra-high-throughput spiral device 102 consisting of three stacked spiral 
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microfluidic chips with two inlets and two outlets, in which the combination of the inertial 
and Dean forces focuses the cells at certain equilibrium positions of the channel cross-
section. Khoo et al. published an improved version of this technology with clinical 
validation using a large number of clinical samples, and also performed downstream 
immunophenotyping and molecular analyses from isolated CTCs 103, further discussed in 
the next section.  
Dielectrophoresis Methods 
DEP methods are used for isolating CTCs based on cell membrane and cell 
dielectric properties. Using this approach CTCs are generally separated by their response 
to non-uniform electrical fields, since the polarizability of a cell relies on its composition, 
morphology and the frequency of the applied electric field 104. Therefore, using DEP based 
devices allows the identification of cells with different phenotypes. However, compared to 
the two previously described approaches, DEP-based technologies do not show high 
selectivity and have low throughputs (<1 ml hr-1) 79. 
Shim et al. used a continuous flow microfluidic processing chamber into which CTCs are 
isolated from clinical samples using a combination of DEP, sedimentation and 
hydrodynamic lift forces 105. Choi et al. designed a novel DC (direct current) impedance-
based microcytometer that detects changes in DC impedance and exploits size differences 
between CTCs and blood cells 106.  
1.6.1 Advantages of label free approaches 
Physical CTC separation methods have the potential to address the shortcomings 
involved in biological marker based separation methods. Overcoming biased cell selection 
using molecular markers permits heterogeneity studies on CTCs, where different 
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subpopulations can be analyzed. As previously mentioned, CTCs that have undergone 
EMT are associated with a loss of expression for epithelial markers, such as EpCAM and 
Cytokeratin (CK). As a result, the most aggressive cancer cells could potentially be the 
least likely to be captured and identified using EpCAM based technologies 35,41.  
Isolated CTCs can be collected without compromising cell viability or gene 
expression, which in turn enables their molecular characterization. For instance, Shim et 
al. used continuous flow dielectrophoretic field flow fractionation (DEP-FFF) method and 
also performed molecular studies on isolated CTCs 105. For a colon primary tumor, 10% of 
the stained cells had the KRAS G13D mutation, which also reflected the number of cells 
that were stained positive for Cytokeratin. Warkiani et al. performed DNA fluorescence in 
situ hybridization (FISH) to evaluate the HER2 status of isolated CTCs from breast cancer 
patients using their trapezoid chip 101,102. Their results showed that the presence of HER2+ 
CTCs varied across samples and was also observed in samples derived from patients with 
HER2- tumors (2 out of 5). A later spiral technology by Warkiani et al. characterized CTCs 
that were isolated from lung and breast cancer patients by immunophenotyping using cell 
markers such as Pan-cytokeratin, CD45, CD44, CD24 and EpCAM, fluorescence in-situ 
hybridization (FISH) for EML4-ALK fusion or targeted somatic mutation analysis 102. 
They also demonstrated the ability to find matching mutations of the EGFR gene in CTCs, 
cell-free DNA and tumors biopsy specimens 103. 
 Unlike most immuno-affinity based isolation systems which only allow on-chip growth of 
CTCs 64 due to difficulties in post-separation retrieval 72, inertial-based technologies 
simplify CTC culture by using off-chip standard cell culture techniques since cells can be 
recovered in suspension. This advantage gives rise to multiple CTC expansion approaches, 
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such as the use of extracellular matrix (matrigel or collagen) for CTCs growth or a 3D 
culture system 64. Sollier et al. showed that A549 cells processed with the Vortex Chip and 
collected in a well-plate proliferate over 3 days 99. Similarly, Hou et al. used their device 
to demonstrate this advantage by successfully culturing sorted MCF-7 cells for 5 days 63. 
Moreover, they also show the retrieval of intact MCF-7 cell clusters. Despite the high 
throughput of the label free devices, these technologies are still able to preserve cell 
clusters, which are of greater interest to study the metastatic ability of CTCs 16,107. 
In vivo application of label free technologies is still very limited. In one study Zhou et al. 
used their SB microfilter device to perform the only in vivo study currently published using 
a label-free microfluidic device 91. This group demonstrated capture and expansion of 
CTCs originated from two mouse model systems from 4T1 and 4T07 cells. They 
demonstrated tumor formation after injection of 4T1 CTCs and 4T07 CTCs into BALB/C 
mice.  Their study also showed similar tumorigenicity for both CTCs recovered by the SB 
microfilter.  
1.6.2 Disadvantages of label free approaches 
Although on average CTCs are shown to be larger than leukocytes, there is a 
significant overlap in the size of CTCs and leukocytes that may hinder label-free separation 
efforts. The FDA approved CellSearch system has detected CTCs with cell diameters ~4 
µm 28. Marinnucci et al. also reported findings on CTCs that were the same size or smaller 
than leukocytes 108. This variability in size can cause the loss of CTCs or, to overcome such 
problem, low sample purity. Although greatly studied, filter-based approaches encounter 
clogging difficulties when processing large sample volumes 109. This results in flow rate 
discrepancies, which could endanger important performance characteristics ranging from 
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device reproducibility to cell viability for post-processing analysis. Regarding the use of 
DEP, one concern is the effect on the viability of CTCs due to the generation of gases like 
hydrogen and oxygen. Moreover, elevated temperatures may also affect cell viability 110
 22 
Table 1.1 Summary of microfluidic technologies for CTC isolation  
AFFINITY BASED ISOLATION 
Technology Capture Method Flow Rate Capture Efficiency 
details 
Purity Clinical utility Reference 
CTC-chip Affinity (EpCAM) 1 ml hr-1 >60% with different 
concentrations of NCI-
H1650 cells (lung) 
50% Tested with 116 
patient samples (lung, 
prostate, pancreatic, 
breast and colon 
cancers) 
24 
HB-chip Affinity (EpCAM) 1.2 ml hr-1 92% with PC3 cells 
(prostate) 




GEDI chip Affinity (PSMA) 1 ml hr-1 85% in blood with 
LNCaP cells (prostate) 






Affinity (EpCAM) 0.5 ml hr-1 >80% with LNCaP, PC3, 
C4-2 cells (prostate) 






Affinity (EpCAM) 1 ml hr-1 >85% with MCF7 cells 
(breast) 
------ Tested with 20 patient 
samples (breast, 
pancreatic and lung 
cancer) 
44 
OncoBean Chip Affinity (EpCAM) 10 ml hr-1 >80% with H1650 (lung) 
and MCF7 (breast) cancer 
cell lines 
------ Tested with 6 patient 




LABEL FREE ISOLATION 
Device Name Capture Method Flow Rate Capture Efficiency 
details 
Purity Clinical utility Reference 
p-MOFF Size-based 
(Hydrodynamic) 
0.6 ml min-1 93.75% with MCF-7 
91.60% with MDA-MB-
231 









80% with AGS, N87, 




Tested with 5 








3 ml hr-1 >85% with MCF-7 ----- Tested with 20 
metastatic lung cancer 
patient samples 
63 
SB microfilter Size-based 
 
(Filter Pore type) 
Gravity 
driven flow 
83±3%with  MCF-7 
78±4% with  MDA-MB-
231 
----- Tested with 6 
metastatic breast 








(Filter Pore type 
>225 ml hr-1 >90% with 
RT4, T24, HT-1080, 
LNCaP, MCF-7, SK-BR-
3 and MDA-MB-231 
------ Tested with 51 patient 
samples (prostate, 




Vortex Chip Size-based 
(Hydrodynamic) 





57-94% Tested with 12 patient 
samples 








blood in 20 s 
(2400 rpm) 
61% with MCF-7 ------ Tested with 23 patient 
samples 





10 ml hr-1 70-80% 
With MDA-MB-435 and 
MDA-MB-231 
----- Tested with late stage 













blood/ 8 min 
>80 % withMDA-MB-
231, MCF-7 and T24 
~4 log 
depletion 
Tested with 10 patient 
samples 





7.5mL/10min 87.6% with MCF-7 
76.4% with T24 




   
24 





















1.7 The future of microfluidic technologies for the study of CTCs 
The field of microfluidics and CTCs is rapidly evolving. In fact, last year the journal 
Lab on a Chip published a complete CTC-themed issue that highlights some of the new 
technologies along with review papers targeting different aspects, both technical and 
clinical 112. Both affinity and size-based methods of CTC isolation need dramatic 
improvements to their systems to enable highly efficient CTC  recovery 4. Affinity 
isolations have the potential to provide key information that may be missed by size-based 
techniques as outlined in their advantages above. Refinements such as increasing 
throughputs, targeting multiple populations with the use of multiple antibodies may be the 
important steps needed to further improve these technologies. Use of novel materials and 
reversible conjugation of antibodies that may enable CTC release will offer more robust 
CTC analysis modules, as these CTCs can then be utilized for downstream assays 72,113. 
Using immuno-capture methods, different populations of CTCs can be segregated for 
further analysis that may be able to identify tumorigenic CTCs, such as xenograft studies 
114. As for label free technologies, their future is driven by exploiting the physical 
differences between CTCs and leukocytes, with the goal of achieving selective separation 
of CTCs. For example, cell deformability can be combined with CTC size properties to 
develop new label free technologies 79. Regardless of the technological approach, emerging 
technologies should not compromise throughput or sensitivity, while still targeting 
heterogeneous CTCs. 
Past the improvement upon current microfluidic technologies, we predict an increase in 
effort on the molecular understanding of CTCs, encompassing multiple downstream 
analyses that advances personalized treatment. The comprehensive investigation of CTCs 
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is hampered by their low numbers, making this one of the biggest challenges in this field 
33. For better understanding of CTCs, we expect to see an increase in technologies that not 
only aim for the isolation of such cells, but also to perform in situ expansion on such 
devices. For example, Zhang et al. expanded CTCs from early lung cancer patients using 
a 3D co-culture device that used cancer associated fibroblasts and a combination of 
collagen and matrigel to resemble the tumor microenvironment 64. Moreover, we predict 
an increase of label free methods for straightforward retrieval of CTCs from microfluidic 
chips, leading to ex vivo expansion. Recently, several groups have successfully performed 
ex vivo expansion of CTCs from breast cancer 115 and from colon cancer 116. Overcoming 
the limitation of low numbers of CTCs by expanding them will allow for phenotypic and 
genomic characterization of CTCs, which in turn will lead to personalized treatment 
strategies. The establishment of cell lines from cancer patients could guide the course of 
drug therapy at an individual level to ensure optimal treatment outcome.  
Heterogeneity among CTCs makes their isolation and characterization a challenging task. 
The molecular characterization of CTCs has exposed information on the genotype and 
phenotype of these tumor cells and demonstrated a striking heterogeneity of CTCs 117. 
Thus, the present setback is the identification of the functional properties of the different 
CTC subsets. This could be achieved through the use of functional assays that reveal the 
biology of CTCs, with particular emphasis on the discovery of the most aggressive subset 
of CTCs. At present, such assays are limited by the very low concentration and yield of 
CTCs. Single cell studies could serve as an essential tool to assess the heterogeneity among 
CTCs. The study of single CTCs by their molecular characterization provides high clinical 
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relevance by potentially aiding in early cancer detection and revealing new therapeutic 
targets for personalized medicine 118,119. 
While CTC enumeration has shown tremendous potential in terms of clinical utility 120, 
researchers are now exploring their validity as more than just an enumerable measure of 
disease intensity or spread. The prognostic and diagnostic utilities of CTCs are now an area 
of extensive focus through analysis of gene expression profiles 121, single cell analysis 14, 
RNA and DNA studies 5,26, and cytogenetics to detect gene amplifications or 
rearrangements 122,123. Examining epigenetic modifications and their after effects on the 
metastatic cascade may be a useful tool for determining therapeutic efficacy. Chimonidou 
et al. analyzed CTCs and cell-free DNA in breast cancer for methylation of a tumor 
suppressor gene SOX17 promoter 124. In another study of breast cancer, methylation of a 
metastasis suppressor gene was studied in primary tumor and CTCs, and the authors 
investigated its effect on survival 125. Whilst the rarity of CTCs offers challenges in 
enrichment and downstream assay feasibilities, cell free DNA suffer from similar 
limitations with respect to available amounts 126. Malara et al. identified CTC 
subpopulations that are enriched for methylated DNA using folate receptors. Methylation 
of cancer cells is believed to be implicated in metastasis, and the authors found that patients 
with high methylation of CTCs had a risk of relapse 126. Albeit CTC enumeration has seized 
attention as a possible endpoint in clinical trials due to their prognostic utility 127, a 
comprehensive analysis of the genome and epigenome will likely compliment traditional 
diagnostic methods and open the arena for more frequent patient monitoring, leading to 
timely decision making. This also has the potential to circumvent invasive tissue biopsies 
24.  CTCs also offer a means of personalized therapeutics through their tumorigenic 
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capabilities 114. CTC expansion on in vitro microfluidic models, one of which has recently 
been demonstrated by our group 64 propose a method for testing of drugs or drug 
combinations 114,128, which can be used to make quicker decisions for therapeutic 
management. Resistance to treatment can be monitored similarly by analyzing CTCs 26. 
The idea that all of the above could possibly be accomplished through venipuncture, a 
relatively low discomfort means to achieving a higher end, in a field as vast and challenging 
as cancer management, is both an exciting and formidable notion. The future of CTCs thus 
looks promising toward patient-specific tumor monitoring. 
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CHAPTER 2. DEVELOPMENT, OPTIMIZATION AND VALIDATION 
OF LABYRINTH AS A MICROFLUIDIC TECHNOLOGY FOR THE 
ISOLATION OF PANCREATIC CTCs 
2.1 Abstract 
 
Circulating tumor cells (CTCs) present in the blood are the instruments of metastasis 
and are of high biological and clinical relevance. Single-cell technologies are playing an 
increasing role in profiling CTCs in the peripheral blood for detection and real time 
monitoring of cancer metastasis. CTCs also help in identifying its distinct drivers. 
However, current approaches are limited to manual selection of CTCs, which hinders the 
unbiased comprehensive study of CTCs on a single cell level. A unique label-free 
microfluidic “Labyrinth” device is presented in this chapter. This device isolates CTCs at 
a high throughput of 2.5mL/min, offering the first biomarker independent single cell 
isolation and genomic characterization platform to study heterogeneous CTC 
subpopulations in cancer patients. The Labyrinth takes advantage of inertial forces on the 
microscale in curved geometries to differentially focus cells based on their size. This novel 
strategy of multi-course path traversing across inner loops to outer loops yielding highest 
hydrodynamic path length enabling focusing of white blood cells (WBCs), leading to high 
recoveries (> 90%) and efficient separation of WBCs from CTCs, resulting in high purity 
(~ 200 WBCs/mL), even in whole blood samples without any pre-processing. The 
Labyrinth platform allows a thorough molecular understanding of the heterogeneity among 
CTCs. This platform also shows CTCs potential as a biomarker to non-invasively evaluate 
tumor progression and response to treatment in cancer patients. 
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2.2 Introduction 
Circulating tumor cells (CTCs) found in the peripheral blood of cancer patients are 
often indicators of metastasis21,28. The study of CTCs has clinical potential as a prognostic 
biomarker to predict treatment efficacy, progression-free survival, and overall survival in 
patients10,30,129-131. Additionally, molecular analysis of CTCs using single cell technologies 
may facilitate the selection of molecularly targeted therapies and assess the efficacy of 
these treatments.  
The clinical and biological relevance of CTCs makes their isolation an active area 
of research, bolstered by several technological developments over the past 15 years132. 
Technologies taking advantage of microfluidic principles to manipulate cells are 
establishing their niche and are an active area of research110. These approaches are mainly 
categorized by their exploitation of either CTCs’ distinctive biological or physical 
properties (Table 1.1). The most widely used microfluidic approach for isolation of CTCs 
is immune-affinity capture using distinct antibodies targeting molecules that are expressed 
exclusively on tumor cells and are absent in blood cells. The most commonly used antibody 
for isolation of CTCs is against the epithelial cell adhesion molecule (EpCAM). This 
strategy has been successfully validated for use in prognosis, therapeutic monitoring and 
molecular diagnosis15,24,26,36,111. However, it is now widely accepted that CTCs can have 
heterogeneous expression of cell surface markers, including EpCAM, and that some CTCs 
might not express EpCAM at all. Furthermore, these technologies cannot achieve 
downstream single cell analysis due to their inability to release CTCs that are captured on 
the device24,36,111.  
In an attempt to move away from affinity based isolation approaches, researchers 
have turned toward size based technologies. CTCs derived from solid tumors show larger 
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sizes compared to the majority of cells in circulating blood. Although these size differences 
are small, this finding makes it an attractive strategy for separating CTCs from blood cells. 
In fact, size based filtration techniques are now emerging10,19,86,133. The issues encountered 
with these approaches include pore clogging, high-pressure drop, pre-fixation to prevent 
CTC loss, low throughput, and excessive non-specific cell retention. Other label free 
separation techniques reported in the literature include deterministic lateral displacement 
separation method134, microfluidic flow fractionation approach100, and acoustic based 
separation75. However, one of the common limitations among these techniques is the 
limited flow rate or yet to successfully isolate CTCs from clinical specimens. Recently, 
inertial migration of particles has been introduced and applied in various studies to achieve 
high throughput particle separation based on particle size92. Sun et al., inspired by single 
spiral channel, developed a double spiral microchannel for label-free tumor cell separation 
and enrichment135. Ozkumur et al. applied the inertial focusing in a relatively short 
sinusoidal channels along with lateral displacement and immunomagnetic selection in the 
integrated microfluidic system known as the “CTC-iChip”56. Although this technology is 
promising, an unbiased molecular study of CTCs cannot be achieved due to insufficient 
purity to overcome the ultimate manual selection of CTCs based on a EpCAM+/CD45- 
phenotype136. Hence, we developed a completely label-free and surface expression 
independent microfluidic Labyrinth (Figure 2.1a) to isolate CTCs from blood cells with 
high recovery, while achieving the highest purity among all label-free technologies (Table 
1.1). The Labyrinth platform can facilitate a thorough biological understanding of CTCs 
and their subpopulations, having a direct impact upon patient care for early detection, 
monitoring treatment response, and developing personalized therapy.
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Figure 2.1 Device design and mechanism of Labyrinth. A) Workflow of the Labyrinth system. CTCs are separated through Labyrinth, 
and can be used for downstream analysis or further purified by applying second Labyrinth for single cell analysis. B) Labyrinth loaded with 
red dye and the indication of “loops”. C) SEM image of the outlet design. D) SEM image of the channel and the indication of “corners”. E) 
The separation of labeled WBC/MCF-7 cell line into individual outlets. F) Focusing and separation of labeled WBCs and MCF-7 GFP cells 
along Labyrinth. Cancer cells are focused after traveling for 50 mm from inlet in Labyrinth, while WBCs are focused after 480 mm. Streams 
of cancer cells and WBCs are well separated at outlet. 
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2.3 Methods 
2.3.1 Fabrication of SU-8 mold for Labyrinth 
The mold for the polydimethylsiloxane (PDMS) device is formed from a negative 
photoresist SU-8 100 patterned using soft lithography. Using a spin-coater, the negative 
photoresist layer, SU-8 100, is deposited onto silicon wafer rotating at 2450 rpm for 1 
minute.  The wafer is then soft-baked for 10 minutes at 65 °C and 70 minutes at 95°C.  The 
mask is aligned to the wafer and is exposed to UV light for 20 seconds.  Post-exposure-
baking is applied for 3 minutes at 65 °C and 10 minutes at 95°C. Then, the wafer is 
developed by soaking in developer for 6 minutes and in IPA for 1 minute to remove the 
inactivated photoresist. It is hard baked for 4 minutes at 150-180 °C. The height of the 
mold built on silicon wafer is 100 µm, and the width of the channel is 500 µm. 
2.3.2 Fabrication of PDMS device 
The flow chamber for labyrinth is made from PDMS. 30 mL Sylgard polymer base 
and 3 mL curing agent are well-mixed and poured onto a silicon mold. The mixture is put 
in a desiccator for 2 hours to remove bubbles from the mixture. It is then heated at 65 °C 
overnight to harden the polymer. The polymer is cut into the desired shape, and punched 
with needle for tubing. The PDMS device is then bonded to standard sized glass slides via 
plasma surface activation of oxygen. The bonded device is tubed with 0.66 mm diameter 
tubes. 
2.3.3 Sample preparation for spike cell experiments 
A pancreatic cancer cell line with green fluorescent protein (PANC-1/GFP) was 
cultured and mixed with white blood cells (stained with DAPI) in buffer solution (PBS). 
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The MCF-7 breast cancer cell line was stained with Green Cell Tracker (Life Technologies, 
USA) and mixed with a portion of a healthy control blood sample. 
2.3.4 Experimental Protocol for labyrinth. 
The device was pre-flowed with 1% Pluronic acid solution (diluted in 1X PBS) at 
100 µL/min for 10 minutes and then incubated for 10 minutes to prevent cell clotting on 
channel walls. Cell sample suspended in buffer was flowed through the labyrinth at 
different flow rates (1000, 2000, and 3000 µL/min) and was observed under a microscope. 
Product from outlets was collected after 1 minute duration of flow stabilization. Waste 
from each outlet of labyrinth was collected for cell counting to calculate the recovery 
percentage. To observe the isolation of cancer cells from other blood components, images 
and movies were taken using both a high-speed camera and a fluorescence microscope 
under brightfield, FITC, and DAPI filters. 
2.3.5 Measuring cell viability for Labyrinth-processed cell line  
Cell viability was assessed using the MTT ((3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) colorimetric assay. In principle, MTT is taken up into cells 
by endocytosis or a protein-facilitated mechanism and is reduced by mitochondrial 
enzymes to yield a purple formazan product. The ability of cells to reduce MTT provides 
an indication of the mitochondrial integrity and activity, which, in turn, may be interpreted 
as a measure of cell viability [5]. After labyrinth processing, PANC-1 cells were seeded in 
a 96 well plate for 6 days and compared with unprocessed cells (control). Data points were 
taken every 24 hours by adding 8 µL of a 5mg/mL solution of MTT powder in PBS to the 
desired well. Once violet crystals were formed, media was aspirated and 150 µL of 
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isopropanol/0.1% 4mM HCL solvent was added to each well. Absorbance was measured 
at 520 nm using a Microplate reader (Bio-Tek, Winooski, VT). 
2.3.6 Patient Sample Processing  
Labyrinth was pre-flowed with 1% Pluronic acid solution (diluted in 1X PBS) to 
prevent cell clotting on channel walls. Blood samples were then processed through the 
device at a flow rate of 2.5mL/min. Blood samples from pancreatic cancer patients were 
collected into EDTA tubes and processed through Labyrinth with 1:5 dilution with PBS, 
and without any further pre-processing steps. A typical run involves processing of 7.5 mLs 
of whole blood in 15 minutes. Blood samples from metastatic breast cancer patients were 
collected in EDTA tubes and processed through the Labyrinth within 4 hours of collection. 
When samples were processed to ultimately undergo downstream single cell analysis, 
RBCs in blood samples were removed using density separation (6% dextran solution, M.W. 
250,000) prior to the Labyrinth process. The blood sample with dextran solution was kept 
still in room temperature for 45 minutes to bring down the RBCs driven by density 
difference. The supernatant, which includes everything in whole blood except RBCs, was 
carefully taken out using pipettes, and was diluted to 25 mL with PBS. 
2.3.7 Immunostaining protocol of cytoslides  
Samples were permeabilized by applying 0.05% Triton X-100 (PBST) solution for 
15 minutes. Slides were then blocked using 20% donkey serum for 30 minutes at room 
temperature (RT). A cocktail of primary antibodies were added and left in a humidified 
chamber overnight.  The next day, cytoslides were washed thrice with 0.05% PBST for 5 
minutes. Samples were incubated in the dark with secondary antibodies for 45 minutes at 
RT. Finally, samples were washed thrice with 0.05% PBST for 5 minutes and mounted 
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with Prolong Gold with DAPI. Table S7-8 shows the different primary and secondary 
antibodies used in this study. 
2.3.8 Processing of samples using the Double Labyrinth   
Processing samples through LL involves collecting samples from second outlet and 
processing it again through a second Labyrinth device. In cell line experiments, MCF-7 
was pre-labelled with cell tracker and spiked into blood (200/mL) from healthy donors. 10 
mL of spiked blood samples was diluted to 25 mL with PBS buffer solution. The diluted 
samples were processed through first Labyrinth at 2500 µL/min and product from second 
outlet was collected (6 mL). The collected product from first Labyrinth was processed 
through second Labyrinth at the same flow rate (2500 µL/min) and product from second 
outlet was collected as final product. 
2.3.9 Calculation of Log Depletion 
The log depletion for single Labyrinth is calculated based on the initial number of 
WBCs spiked into the samples. After single Labyrinth an average of 96.6% (n = 9) of 
WBCs were depleted into outlet 1, hence resulting in an average of 1.78 log depletion 
(range 1.49-2.23). The log depletion for double Labyrinth is based on the initial number of 
WBCs per mL (~0.7x10^7). The average of 350 WBCs/mL (n = 5) results in a log depletion 
of 4.3 in average (range 3.9-4.5). 
2.3.10 Preparation of Cytospin slides 
Second outlet product was processed using Thermo Scientific™ Cytospin 4 
Cytocentrifuge. 300 µL of sample is added into each cytospin funnel and cytocentrifuged 
at a speed of 800 rpm for 10 minutes. Samples are fixed on the cytoslides using 4% PFA 
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and cytocentrifuged at the same conditions described above. Cytoslides are stored at 4o C 
until further staining.  
2.4 Results 
2.4.1 Labyrinth design and physical principle of separation 
The design of our device is inspired by the Labyrinth in Greek mythology, an 
elaborate structure with numerous turns and corners built to hold the Minotaur. We applied 
a similar structure for the size-based enrichment of CTCs by bulk depletion of 
hematopoietic cells using inertial microfluidics based separation.   
Particle Focusing 
The inertial microfluidics based particle separation relies on the equilibrium 
between inertial lift forces and Dean flow that results in the migration of particles during 
laminar flow in microfluidic devices with curved channels (Figure 2.2). Particles in a 
straight channel experience stresses that act over the entire channel surface, including shear 
stress that yields drag forces and normal stress that yields lift forces perpendicular to the 
direction of flow. The migration of particles due to lift forces was first observed by Segré 
and Silberberg in the 1960s137,138. Di Carlo reported that particles would be maintained at 
specific positions due to the combination of inertial lift forces where shear gradient lift 
pushes the particles toward the wall and the wall lift effect pushes the particles toward the 
center139. These forces will confine the particles in a straight channel to several equilibrium 
positions, where the number of equilibrium positions is related to the geometry of the 
channel.  
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where Re3 is the particle Reynolds number, Re, is the channel Reynolds number, and 1, 
is the position of the particle within the channel. 
Particle Separation 
 The Dean flow, on the other hand, occurs in the flow in curved channels. Dean 
flow is secondary flow due to the centrifugal effects that will affect the particle equilibrium 
positions141. Dean flow is characterized by counter-rotating vortices where the flow at the 
midline of the channel is directed outward around a curve, while the flow at top and bottom 
of the channel is directed inward141. The drag force due to Dean flow (FD) is correlated 
with the particle size and curvature of the channel, and this drag force will also affect the 
equilibrium position of the particles. Therefore, the equilibrium between inertial lift forces 
and the drag force from Dean flow can be utilized for size-based sorting135. 
In the presence of inertial lift forces that keep a particle in a stationary position, an 
expression of drag force FD is raised by Di Carlo92: 
!4	~	789
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where 89 is the maximum channel velocity, : is the particle diameter,	;< is the hydraulic 
diameter, and = is the radius of curvature of the channel. 
The lift forces stabilize particles at positions located along the centerline of a 
channel cross section, while Dean flow drag forces cause particles to migrate around the 
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Cell Separation 
CTCs can be isolated from other blood cells in curved microfluidic devices by 
focusing different sized cells into different streamlines and collecting them into individual 
outlet channels. The inertial force can be considered as the driving force that focuses the 
particles, while the drag force from Dean flow is the force that causes particle migration 
away from the center of the channel, leading to size-based separation (Figure 2.2).  
Giving the fact that Fz is proportional to the square of particle size (Eqn. 1), blood 
cells are more difficult to focus in microfluidic channels due to their smaller size compared 
to CTCs. It has been proposed that sharp curves enhance the focusing of smaller 
particles135,142. To focus the relatively smaller cells found in blood such as WBCs, a 
microfluidic device must contain curves with a high curvature ratio. 
Besides the focusing of particles, it is also crucial to have the proper curvature for 
sized separation (Figure 2.2). In the situation of high curvature ratio where FD dominates, 
particles could be dispersed and lose their focusing due to the insufficiency of Fz, or all the 
particles with different sizes could be pushed to the same focusing position due to the 
strong migration force (FD)142. In a curve with extremely low curvature ratio where Fz 
dominates, particles with different sizes remain at the same equilibrium positions similar 
to a straight channel due to the limited migration force142. An accurate design of curves in 
the microfluidic structure would lead to the focusing of cells while separating CTCs and 
blood cells by size.  
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2.4.2 Labyrinth Design 
The total channel length of Labyrinth is 637 mm. It is 500 µm in width and 100 µm 
in height. It consists of 11 loops and 56 corners. The loops (Figure 2.1b), which have a 
small curvature ratio (K) (Eqn. 4) range from 5.29x10-3 to 3.70x10-2 m-1, and were 
incorporated into the Labyrinth to provide enough length of channel to achieve total 
focusing of cells and to have the proper curvature for the separation between CTCs and 
Figure 2.2 Physics of the Labyrinth. Physics of Labyrinth. a, Particle on a channel is 
focused by lift forces, which includes the force from shear gradient and from wall effect. 
When the two forces are balanced, the particles reach their equilibrium position. b, In a 
curved channel, the fluid close to the inner wall will be drawn away from the center of 
curvature by centrifugal force, causing two vortices to appear at top and bottom, 
accordingly. c, Particles will be focused to several equilibrium positions in microfluidic 
channels. For square channels, there will be 4 equilibrium positions and for rectangular 
channels, there will be 2. d, Desired focusing position occurs when ratio for the larger 
particle is greater than the ratio for small particle, and the ratios are not too close to 1 nor 
too greater than 1. At such position, the particles can be well separated. 
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blood cells (Figure 2.1 e, f). The 56 sharp right-angle corners (Figure 2.1d), which have 
high curvature ratio, further enhance the focusing of smaller cells without the need for 
positive or negative selection. The channel width expands to 1000 µm from 500 µm before 
the streams are diverted into the outlets (Figure 2.1c).  The outlets were designed such that 
the focused individual streams could be collected separately (Figure 2.1e).  
2.4.3 Cell Focusing in Labyrinth 
To demonstrate cell focusing in the Labyrinth, DAPI-labeled WBCs with GFP-
labeled breast cancer cells (MCF-7) were mixed in PBS buffer and flowed through the 
Labyrinth. Figure 2.1f presents a fluorescent image (green: MCF-7 GFP; blue: WBCs) of 
the entire device. The corners in the device are numbered in sequential order from inlet to 
outlet. Cancer cells in the Labyrinth started focusing at corner #5 (50 mm from inlet), 
whereas WBCs became focused at corner #47 (480 mm from inlet), as shown in Figure 
2.1f. The difference in the length needed for the cells to be focused resulted from the 
magnitude of lift force, which was proportional to the fourth power of particle size (Eq. 1). 
Given the smaller cells encounter lower lift forces compared to big cells, it is harder to 
focus the smaller cells in inertial fluidics devices.  Smaller cells require longer time to come 
to the equilibrium positions as the force experienced by them is much smaller compared to 
bigger cells. Hence the smaller cells need longer travel distance to be able to focus fully. 
Additionally, Labyrinth design incorporated multiple turns to aid the focusing of smaller 
cells further. Focused WBCs were sorted out into the first outlet and the CTCs stream was 
collected through the second outlet as shown in Figure 2.1e. 
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2.4.4 Testing and optimization of Labyrinth for cell recovery 
The Labyrinth was optimized and tested for inertial separation of cancer cells using 
human breast (MCF-7), pancreatic (PANC-1), prostate (PC-3) and lung (H1650) cancer 
cell lines. It was determined that the optimal flow rate for maximized recovery and purity 
was between 2.0-2.5 mL/min (Figure 2.3) after the first 60sec, which are used for the flow 
to stabilize in the device for optimal collection (Figure A.5). Pre-labeled (Cell Tracker) 
cancer cells and WBCs were spiked at a high concentration (~100,000/mL and 
~500,000/mL, respectively) into buffer and separated using the Labyrinth. Using MCF-7 
cells, 91.5 ± 0.9% of cancer cells were recovered from the second outlet while 91.4 ± 3.3% 
of WBCs were removed through the first outlet (Figure 2.4a, n=3). With GFP-labeled 
PANC-1 cells, a similar separation was achieved, with 92.4 ± 3.2% recovery of cancer cells 
with 89.0 ± 1.1% of WBCs removed in the first outlet (Figure 2.4a, n=3). Labyrinth 
recovery was further tested with other solid tumor cell type such as lung and prostate and 
found the yields to be similar (Figure 2.4a). MCF-7 and PC-3 cells were spiked into whole 
blood and run through Labyrinth without any pre-processing. The recoveries even from 
whole blood are higher than 90% (Figure 2.4a) demonstrating the ability of Labyrinth to 
isolate CTCs directly from whole blood. Separation of cancer cells from other blood cells 
was visualized using a high speed camera and, as shown in Figure 2.4b, the cell streams 
were physically separate, enabling high purity isolation of the cancer cell population. To 
further characterize the ability of the Labyrinth to isolate lower concentrations of CTCs 
(100/mL), MCF-7/GFP cells were spiked into buffer and  into healthy donor blood samples, 
and then processed through the Labyrinth. In this set of experiments, when spiking into 
blood, blood is treated with Dextran following the spike to remove excess RBCs and see 
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its effect on recovery. The average recovery in buffer solution was 94.4 ± 3.8%, while in 
RBC depleted blood a 95.3 ± 0.7% recovery was obtained (Figure 2.4c). Importantly, an 
MTT assay demonstrated that the shear stress experienced by cells processed through the 
Labyrinth did not have a significant effect on cell viability or proliferation rates (Figure 2.4 
d, e).  
 
 
Figure 2.3 Flow rate optimization for pancreatic CTC isolation. PANC1 
recovery optimization. a, PANC1 cell line recovery measured at different at flow 
rates ranging from 1-3 mL/min. b, WBC removal measured at different at flow rates 
ranging from 1-3 mL/min. 
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2.4.5 Double Labyrinth Separation for higher specificity 
Processing of samples through a single Labyrinth even at a flow rate of 2.5 mL/min, 
which is considerably greater than the currently available label-free techniques yielded 
comparable or better purity (13800 WBCs/mL average, n=9, compared to 32,000 
WBCs/mL reported56). However, to further increase CTC enrichment for high content 
downstream molecular assays at single cell resolution we adopted the strategy of using a 
double Labyrinth (LL), two single Labyrinth devices applied in series. This system furthers 
reduce the WBC contamination yet maintains equivalent CTC viability. As shown in 
Figure 2.4 f, g, the recovery of MCF-7 cells using a double Labyrinth (91.1 ± 0.7%) was 
consistent with the results obtained using a single Labyrinth (91.5 ± 0.9%), but with lower 
WBC contamination (663 ± 647 WBCs/mL), representing a two-log improvement in tumor 
cell enrichment over the single Labyrinth. This mode of operation yields by far the highest 
purity reported using the label-free methods. It is to be noted that the additional run through 
Labyrinth does not significantly add to the processing time (<5 minutes). A detailed 
comparison of the performance metrics between Labyrinth and other microfluidic 
technologies and all other technologies (macro or micro) are provided in Table A.6, 
demonstrating the advantages of Labyrinth in terms of high flow rate, high yields, high 
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Figure 2.4 Control experiments with spiked cancer cell lines using Labyrinth A) 
Recovery results from each outlet of the Labyrinth for four different cancer cell lines: breast 
(MCF-7), pancreatic (PANC-1), prostate (PC-3) and lung (H1650) cancer along with white 
blood cells (WBCs). PANC-1, H1650, and MCF-7 were spiked into RBC-removed blood, 
whereas MCF-7 and PC-3 were spiked into whole blood. B) High speed camera image 
showing Labyrinth’s ability to separate WBCs from cancer cells through first and second 
outlet.  C) Recovery results from second outlet using 100 MCF-7 cells for both buffer 
experiments (n=4) and spiked cells in whole blood (n=3).  D) MTT assay results for 
Labyrinth-processed PANC-1 cells and cultured over a period of 7 days. E) Fluorescence 
image showing morphology preservation of PANC-1 cells processed at 2.5 mL/min. F) 
Comparison of recovery efficiency using a single or double Labyrinth for each outlet. Error 
bars represent the standard deviation of three replicates. G) Log depletion of WBCs using the 
single (n=9) and double Labyrinth (n=10) to demonstrate high device purity 
 
   
46 
 
2.4.6 Isolation of CTCs from pancreatic cancer patients 
CTC analysis was performed using blood samples collected from 20 patients with 
a new diagnosis of pancreatic cancer, as shown in Figure 2.5a. These whole blood samples 
were all processed without any pre-processing as described in methods. All of the samples 
had measurable CTCs, identified as DAPI positive nucleated cells staining positive for CK-
19 and negative for CD45, as shown in Figure 2.5b. CTC Enumeration in these twenty 
patients showed a yield of 51.6 ± 25.5 pancreatic CTCs per mL blood, whereas less than 2 
CTC-like cells/mL were found in healthy controls. Patient demographics are provided in 
Table A.7. These results demonstrated that the Labyrinth is capable of isolating patient 
derived CTCs directly from whole blood with high sensitivity. 
Pancreatic CTCs were further evaluated to determine what percentage of the cells 
displayed epithelial versus mesenchymal-like features. To quantitate epithelial-like cells, 
expression of EpCAM and CK-19 was assessed, while for quantification of mesenchymal-
like cells, the EMT markers ZEB1 and ATDC were used. All patient samples contained 
not only CK+ CTCs but also EMT marker positive CTCs. An average of 53 ± 17% of the 
captured CTCs stained positive for EMT-related markers along with CK-19. Figure 3c 
presents three CTC subpopulations obtained from the same patient differentially 
expressing epithelial and mesenchymal markers, demonstrating intra-patient CTC 
heterogeneity.The molecular characteristics of CTCs were explored by mutational analysis 
of select genes using the DNA isolated from captured CTCs. DNA was extracted from five 
pancreatic patient samples, where patient demographics are shown on supplementary table 
A.9. The qBiomarker Somatic Mutation PCR Array: Human Pancreatic Cancer (Qiagen) 
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was chosen to represent a comprehensive spectrum of frequently mutated genes in 
pancreatic cancer. The array includes multiple assays for genes including APC, BRAF, 
CDKN2A, CTNNB1, KRAS, NRAS, PIK3CA, SMAD4 and TP53. Using this array, 
mutations were detected in all samples tested involving at least one of the genes (Table 
A.8). All of the samples tested were positive for KRAS. As expected, no mutations were 






Figure 2.5 Isolation of CTCs directly from whole blood (without any additional pre-
processing steps) collected from pancreatic cancer patients using single Labyrinth. A) 
Percentage of CTCs expressing both EMT and epithelial markers vs only epithelial 
markers. Column on the bottom indicates the total CTCs (CK+, CD45-, DAPI+) per mL of 
blood for each patient. B) Fluorescence microscope images of CTCs from patient samples 
and white blood cells stained with DAPI (blue), cytokeratin (red) and CD45 (green) C) 
Immunocytochemistry analysis performed on a metastatic sample where both epithelial 
and EMT-like CTC subpopulations were found. Scale bar 10 µm. 
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2.5 Discussion 
CTCs are critical to understanding the biological process of metastasis and could 
serve as potential biomarker to noninvasively evaluate tumor progression and response to 
treatment. There is a substantial evidence that CTCs released from the primary tumor travel 
through the blood to distant anatomic sites and contribute to the development of lethal 
metastases. The development of technologies capable of isolating and molecularly 
characterizing these rare cells at single cell resolution should facilitate studies into their 
biology and the mechanisms of metastasis. Isolation strategies should not only be efficient 
and sensitive but also should be unbiased with regard to surface expression. In this respect, 
microfluidics have allowed for an unprecedented spatio-temporal control of cells4. While 
its application for cancer research is nascent, a number of studies have demonstrated its 
feasibility in the isolation and characterization of CTCs from clinical samples. In order to 
sort the WBCs from CTCs in a truly label-free fashion we developed a novel strategy using 
inertial microfluidics that not only uses the delicate balance of inertial and Dean forces to 
differentially focus cells, but also induces fluidic path directional shift by incorporating 56 
high curvature turns. Unlike other inertial focusing methods, the multi-course path 
traversing across inner loops to outer loops yields highest hydrodynamic path length 
(637mm) to enhance the focusing of both CTCs and WBCs resulting highest purity (Table 
A.6). 
With the presented Labyrinth, we were able to demonstrate a high throughput, 
continuous, and a true biomarker independent (without positive or negative selection) 
microfluidic separation technology to isolate CTCs from whole blood. Classical genomic 
analysis techniques use population average readouts. However, these approaches mask 
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cellular heterogeneity and dynamics and are limiting for studying rare and heterogeneous 
cell populations, including cancer stem cells. We demonstrated that the cells isolated using 
Labyrinth contain subpopulations of CTCs expressing markers of epithelial and 
mesenchymal stem-like cells.  
Over the past several years, a tremendous amount of effort has been invested in the 
development of new therapeutic agents that can take advantage of the “Achilles’ heel” of 
CSCs by targeting cell-surface molecular markers or various signaling pathways. A 
number of agents capable of targeting breast and pancreatic cancer stem cells in preclinical 
models are currently entering clinical trials143. Assessment of the efficacy of the agents will 
require development of innovative clinical trial designs with appropriate biologic and 
clinical end points. The lack of proper biomarker endpoints has resulted in difficulty in 
assessing the effects on CSCs in these studies. The high throughput Labyrinth enables 
single cell isolation and creates opportunities to monitor heterogeneous subpopulations 
through treatment. Future research will involve more extensive application of innovative 
microfluidic systems that target the use of CTCs as a reliable biomarker for early detection, 
treatment selection, and monitoring of cancer patients
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CHAPTER 3. APPLICATION OF LABYRINTH TECHNOLOGY FOR 
THE ISOLATION OF CTCs IN PANCREATIC PATIENT SAMPLES: A 
CLINICAL STUDY 
3.1 Abstract 
Pancreatic cancer has lowest overall survival rate among all types of cancer. One of the 
major challenges with pancreatic cancer is our inability to detect it in early stages. This is 
due to the vagueness and non-specificity of its symptoms, which are commonly confused 
with those of other diseases. Due to the aggressive nature of pancreatic cancer, the 
likeliness of tumor invasion to other organs at the time of diagnosis is uncharacteristically 
high (when compared to other solid tumors). While no curative alternative is available for 
this diagnosis, current treatment options retard tumor progression. Here, we investigate the 
utility of CTCs as a tool for assessing tumor response to the only three therapy options 
available for pancreatic cancer. For this study CTCs were isolated using the label free 
Labyrinth technology, followed by the enumeration of total and EMT-like CTCs. Over 150 
treatment naïve samples were tested for CTCs, with 83% of patients displaying an 
aggressive EMT-like CTC subpopulation. This cohort was further stratified by each 
patient’s treatment options: surgery, chemotherapy, and radiotherapy. CTCs were 
measured at two time points for each of the treatment courses (pre-/post- treatment). For 
all treatment cohorts, we observed a statistically significant decrease in CTC count after 
treatment completion.  The use of CTC for predicting overall survival of the patient was 
also investigated. Results showed a trend toward correlation of a decrease in CTCs with 
higher survival probability for all treatment options. However, only in chemotherapy 
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treated patients we could observe a statistically significant p-value. Our work highlights 
the clinical utility of CTCs as a biomarker for treatment monitoring in pancreatic cancer. 
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3.2 Introduction  
The incidence of pancreatic adenocarcinoma is increasing and it is projected to be 
the second most common cause of cancer death by 2030.  This projected increase is thought 
to be secondary to the aggressive biology of the disease in combination with the shifting 
population demographic created by the aging baby boomers144.  Patients are often 
diagnosed with pancreatic cancer at an advanced stage as the diagnosis of pancreatic cancer 
can be difficult due to absent or ambiguous symptoms, and a lack of screening 
biomarkers145. There is a great need to find an effective and economical tool for diagnosis, 
prognosis and predictive decision making in the field.  Recent advances in endoscopy have 
made access to pancreatic lesions for tissue diagnosis slightly less challenging, however, 
the false negative rates is up to 20% for fine needle aspirate and 19-30% for brush 
cytology146-148. The invasive nature of the procedure does not lend this technique to routine 
repeat biopsies that may be used to assess pharmacodynamic responses during clinical 
trials or to develop predictive biomarkers. 
Recent work focusing on isolation of circulating tumor cells (CTCs) in cancer 
patients, including pancreatic cancer, holds promise to fill this technological gap.  This 
concept capitalizes on the nature of pancreatic cancer to metastasize hematogenously early 
in the disease process. Tumor cell dissemination may be as a result of passive shedding or 
as a result of acquired characteristics by cells through a process of epithelial to 
mesenchymal transition (EMT)149,150.  Studies in genetically engineered mouse models of 
pancreatic cancer have demonstrated that tumor cells can be found circulating in the blood 
prior to histological evidence of tumor development in the pancreas151. This suggests that 
a similar process may occur in patients, and access to these circulating tumor cells would 
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provide vital diagnostic information about patients at high risk for developing pancreatic 
cancer.  
Approximately 85% of the patients that undergo surgery for pancreatic cancer will 
eventually relapse and die of their disease144. This information suggests that many of these 
patients might have circulating tumor cells at the time of surgery, and therefore they may 
have disease beyond the pancreas, although it cannot be detected with current clinical 
detection methods, which typically involves CT scan148. This observation has led to an 
increasing popularity in the use of neoadjuvant chemotherapy to treat any systemic disease 
for some patients prior to surgery, even in the setting of resectable disease152.  Given the 
improvement in survival in some subsets of patients with neoadjuvant chemoradation153 
we sought to examine the impact of therapy on circulating tumor cells in patients before 
and after therapeutic intervention. 
Through joint efforts in the field of medicine and bioengineering multiple platforms 
exist to enrich patient blood samples for CTCs. The number of CTCs in cancer patients are 
typically quite low in peripheral blood (~1 CTC for every 107 blood cells), and thus 
presents significant technical challenges in detection and isolation from other blood 
components149,154-156. Among the technologies that have been developed to enrich for CTCs 
from other blood components, the vast majority can be classified as either based on CTC 
antigenic and immunoaffinity characteristics, or physical properties. Following isolation, 
the identification of CTCs is typically performed by immunofluorescence staining for cells 
that are positive for cytokeratin and/or EPCAM (indicating their epithelia origin) and 
negative for CD45 (ruling out hematopoietic cells) and positive for DAPI (nuclear stain). 
The overall goal of the many different approaches that have been developed is to facilitate 
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detection of CTCs from among the millions of other contaminating blood cells and then to 
employ mechanisms to isolate or immobilize the cells so that cells can be further analyzed.  
To date there is only one FDA approved for clinical use in the USA. The CellSearch® 
system, (Janssen Diagnostics, Raritan, NJ, USA) was approved for use by the FDA in 2004 
and it involves immunomagnetic capture of CTCs through formation of an EpCAM 
antibody-antigen complex157. CTCs are then identified by negative stains for CD45 and IF 
staining for nuclear content with DAPI as well as cytokeratins (CK) 8, 18 and 19. This 
technology has successfully detect elevated levels of CTCs in patients with metastatic 
cancers of the breast, colon, prostate and lung,21,158-161 however; in a trail of 79 patients 
with locally advanced PDA the detection rate was low at 11% using the CellSearch 
platform162. Given to low yield in pancreatic cancer CTCs with an immunoaffnity based 
approach using EPCAM, we developed a platform that enriches CTCs from patient blood 
samples based on physical properties. The Labyrinth is a high throughput, label-free 
microfluidic device that separates cells based on their diameter through the use of inertial 
forces. The Labyrinth consists of a microfluidic channel that utilizes multiple curves as 
well as 56 sharp corners to create this separation (Chapter 2). The Labyrinth contains four 
outlets where the CTCs, which are larger than white blood cells, exit the device in the 
second outlet with a high recovery of >90%. WBCs are depleted from the first outlet, 
achieving an 89% WBC removal from the sample. Its high flow rate of 2000 µL/min 
enables short processing time of 11 minutes for a standard 10mL EDTA tube. To evaluate 
the utility of the labyrinth as a platform for CTC enrichment in pancreatic ductal 
adenocarcinoma we prospectively collected over 150 samples from the multi-disciplinary 
Pancreatic clinic at University of Michigan between 2014 – 2016. 
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3.3 Methods 
3.3.1 Patient sample processing 
Labyrinth is pre-flowed with 1% Pluronic acid solution (diluted in 1X PBS) at 100 
µL/min for 10 minutes to prevent cell clotting on channel walls. A full tube of whole blood 
(~7-10mL) was collected for each patient and processed for CTC enumeration. RBCs in 
blood samples were removed using density separation (6% dextran solution, M.W. 
250,000) prior to the Labyrinth process. The blood sample with dextran solution was kept 
still in room temperature for 1 hour to bring down the RBCs driven by density difference. 
The supernatant, which includes everything in whole blood except RBCs, was carefully 
taken out using pipets, and was diluted with PBS buffer at a 1:3 ratio. Blood samples were 
then processed through the device, at a flow rate of 2 mL/min. 
3.3.2 Preparation of cytospin slides 
Second outlet product is processed using Thermo Scientific™ Cytospin 4 
Cytocentrifuge. 300 µL of sample is inserted into each cytospin funnel and cytocentrifuged 
at a speed of 800 rpm for 10 minutes. Samples are fixes on the cytoslides using 4% PFA 
and cytocentrifuged at the same conditions described above. Cytoslides are stored at 4o C 
for further staining.    
3.3.3 Immunostaining protocol of cytoslides from patient samples  
Samples were permeabilized with Phosphate Buffered Saline with 0.05% Triton 
(PBS-T) solution for 15min and blocked using 10% donkey serum for 30 minutes at RT. 
Rabbit anti-human Zeb1 ( 1:500 Santa Cruz sc-25388), Mouse IgG1 anti-human anti-Pan-
Keratin (1:500 Biolegend 628601), Mouse IgG2a anti-human anti-Cytokeratin 19 (1:500 
Santa Cruz sc-6278) and Rat IgG2b anti-human CD45 (1:500 Santa Cruz sc-70699) in 
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blocking buffer and applied to samples overnight in a refrigerator at 4oC The next day, 
samples were washed for five minutes with PBS-T (3X). Donkey anti-rat AF FITC 488 
(1:500 Life Technologies A21208), Donkey anti-mouse APC 647 (1:500 Life 
Technologies A31571) , Donkey anti-rabbit 568 TxRed (1:500 Life Technologies A10042)  
were diluted in blocking buffer and applied to samples, which were incubated in dark for 
45min at RT. Samples were again washed 3 times for 5min with PBS. DAPI (1µg/ml, 
Thermo Fisher) diluted in PBS was applied for 10min at room temperature to label nuclei. 
A drop of Prolong® Diamond Antifade Mountant (Thermo Fisher) was then added and 
coverslips were mounted onto the slides for imaging. 
3.3.4 Statistical Analysis  
 Covariates including CTC total, epithelial CTC, EMT like CTC, stage, age, sex and 
CA19.9 were collected at different time points of the study. Spearman’s rank correlation 
was used to for correlation analysis because of the non-normality of the covariates. Paired 
Wilcoxon signed-ranked test (median) and one sided paired t-test (mean) were used to 
compare the covariates pre-surgery vs post-surgery, pre-chemotherapy vs on-
chemotherapy vs post-chemotherapy, and pre-radiation vs post-radiation.  
 For treatment naïve patients, the overall survival (OS) time was the time of first 
data collection to death or last follow-up. For the surgery, chemotherapy and radiation 
patients, the overall survival time was the time of surgery or start of treatment to death or 
last follow-up. For the surgery patients, the recurrence-free survival was the time of surgery 
to recurrence or last follow-up. Since some of the overall survival time is right censored, 
the non-parametric Kaplan-Meier estimator was used to estimate the survival function of 
patients. Logrank test was used to test the difference in survival curves by different groups. 
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To estimate the effect of baseline covariates such as stage, CTC and CA19.9, univariate 
and multivariate cox-ph models were built and compared. 
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3.4 Results  
3.4.1 CTC isolation in pancreatic cancer patients using the Labyrinth 
 The Labyrinth was tested and optimized for the inertial separation of pancreatic 
cancer cells (PANC1). It was determined that the optimal flow rate for maximal recovery 
and purity was 2.0 mL/min and that it took 60 sec for the flow to stabilize in the device for 
optimal collection (Chapter 2). Under these conditions, PANC1 cells were spiked into 
whole blood at different cell concentrations ranging from 10-100K. In all cases, recovery 
was above 88%, proving that the Labyrinth could be used to process clinical samples, 
where low numbers of CTCs are expected (Figure 3.1b). 
To examine the clinical utility of the Labyrinth, CTCs were isolated using size 
based separation by Labyrinht, and then the isolated CTCs were fluorescently stained and 
enumerated. Blood samples were collected from 358 patients diagnosed with pancreatic 
cancer.Taking advantage of the Labyrinth’s label free approach, CTCs were enumerated 
for each patient and classified as either Epithelial-like or EMT-like CTCs. Epithelial-like 
CTCs were expected to be cancer-specific, panCK positive, DAPI positive, and CD45 
(white blood cell marker) negative. EMT-like CTCs were identified by the coexpression 
of panCK and Zeb1, a commonly reported EMT-related marker in pancreatic cancer163, in 
addition to being DAPI positive and CD45 negative. The total number of CTCs was equal 
to the sum of the two subpopulations as per the classifications described. Patients from the 
treatment naïve cohort underwent commonly-used treatments for pancreatic cancer, such 
as surgery, chemotherapy, and radiotherapy. These patients were used to study the 
correlation of CTC counts with treatment monitoring and efficacy, as shown in Figure 3.1a. 
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Figure 3.1 CTC isolation in pancreatic cancer patients using Labyrinth a. 
Experimental outline for this clinical study. b. Cell spike experiments using PANC1 cell 
line at several concentrations 
 
3.4.2 CTC enumeration for treatment naïve cohort 
Treatment naïve pancreatic cancer patients (n = 153) were classified according to 
their tumor staging: (1) resectable (n = 40), (2) borderline resectable (n = 34), (3) locally 
advanced (n = 25), and (4) metastatic (n = 54). Patient demographics are listed in Table 
3.1. Figure 3.2a shows the total CTC counts per mL and the EMT-like CTC counts per mL 
of whole blood for all patients, which ranged from 0-117 CTCs/mL and 0-50 EMT-like 
CTCs/mL, respectively. Box plots were created for statistical analysis of each stage (Figure 
3.2b and 3.2c). High variability was observed across all stages. Statistical significance was 
only observed between resectable and borderline resectable stages (p = 0.03, paired t-test); 
where borderline resulted in higher CTC counts than resectable. EMT-like CTCs had 
similar values across all stages. No statistical significance was observed between the stages 
for EMT-like CTCs. The presence of EMT-like CTCs in the early stages of pancreatic 
cancer development highlights the aggressiveness of this particular type of cancer. Figure 
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conclusion of this study, 79 patients (52%) had been declared deceased. The median 
survival time of the treatment naïve cohort was 1.33 years (95% CI: 1.18-1.70). 
Furthermore, their two-year survival probability was 0.248 (95% CI: 0.165-0.371). Figure 
1e shows the survival probability across all stages. A log-rank test yielded significant 
results (p < 0.001). The survival probability decreased significantly with stage progression, 
with borderline resectable having the highest two-year survival probability (0.505) and 
metastatic having the lowest (0). Median times for each category are listed in Appendix B.	
Representative images of epithelial-like and EMT-like CTCs from several patients are 
shown in Figure 3.3. Despite the size of CTCs being highly variable in these images, CTCs 
in general were larger than WBCs. Most patients (83%) tested positive for EMT-like CTCs, 
as indicated by cytoplasmic coexpression of panCK and Zeb1. 
 
Table 3.1 Patient demographics for treatment naïve cohort 
Variable Mean Median Range 
Age 65.3 66.0 34-86 
Total CTC 18.04 12.00 0-117 
Epithelial CTC 9.445 3.000 0-80 
EMT-like CTC 8.863 6.000 0-50 
CA19-9 13695 329 2-1393634 
    
Variable Categories Count Percent 
Gender Female 72 47% 
 Male 81 53% 
Stage Resectable 40 26% 
 Borderline resectable 34 22% 
 Locally advanced 25 17% 




   
62 
 
Figure 3.2 CTC enumeration for treatment naïve cohort. a. Enumeration of epithelial 
and EMT-like CTC for treatment naïve pancreatic cancer patients. b.  Box plot for total 
CTC counts stratified by cancer stage. c. Box plot for EMT-like CTC counts stratified by 
cancer stage.  d. Kaplan Meier curve for overall survival probability in treatment naïve 
patients e. Kaplan Meier curve for overall survival probability in treatment naïve patients, 
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3.4.3 CTC enumeration for pre- and post-surgery cohort 
Changes in CTC counts were evaluated for pancreatic cancer patients undergoing 
surgery. Blood samples were collected 22 days (median) prior to surgery and 33 days 
(median) post-surgery, for a total of 29 patients. Patient demographics for the pre- and post-
surgery patient cohort are listed in Table 3.2. A box plot of the data, shown in Figure 4a, 
revealed a decrease in CTC counts after surgery, which is statistically significant (p = 
0.036). Figure 3.4b and 3.4c show the overall survival and disease recurrence for this 
cohort, respectively. Of the 29 patients examined, 10 had recurrence of the disease and 4 
were declared deceased. Further analysis was performed by classifying the cohort based 
on cancer stage. 22 out of 29 patients were classified as resectable, while the remaining 7 
were classified as borderline resectable. Figure 3.4d shows a statistically significant 
difference for the change of CTC for pre- and post-surgery sample between stages (p = 
0.00122). In both stages, there was a decrease in CTC counts as a result of treatment. In 
the pre-surgery group, borderline resectable CTC counts were higher than those of 
resectable. In the post-surgery group, resectable CTC counts were higher than those of 
borderline resectable. The decrease in CTC counts for the borderline resectable category 
was greater than that of the resectable category, suggesting an effect of cancer stage on 
changes in CTC counts. Figure 3.4e and 3.4f show the overall survival and disease 
recurrence for both cancer stages. The borderline resectable category had a higher survival 
probability for both overall survival and recurrence than the resectable category. A log-
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Table 3.2 Statistical analysis of pre- and post-surgery cohort 
Number of patients 29    
Median Age 68   
Range Age 46 to 86   
Gender    
  Male 16 55.2   
  Female 13 44.8   
Median (range) number of days pre-surgery -22 (0-243)  
Median (range) number of days post-surgery 33 (0-616)  
Total 
CTCs 
         
Median (pre) 13 Mean (pre) 21.83 
  Median (post) 6 Mean(post) 11.69 
  Median difference b/w pre and post -1 Mean difference b/w pre and post -10.14 
 Paired Wilcoxon signed-ranked test 0.035* Paired t-test p-value 0.036* 
Epithelial 
CTCs 
         
Median (pre) 3 Mean (pre) 10.28 
  Median (post) 0 Mean(post) 4.45 
  Median difference b/w pre and post 0 Mean difference b/w pre and post -5.24 
 Paired Wilcoxon signed-ranked test 0.076 Paired t-test p-value 0.10 
EMT-like 
CTCs 
         
Median (pre) 6 Mean (pre) 11 
  Median (post) 5 Mean(post) 7.28 
  Median difference b/w pre and post 0 Mean difference b/w pre and post -2.8 
 Paired Wilcoxon signed-ranked test 0.332 Paired t-test p-value 0.139 
Stage  
  Resectable 22    
  Borderline Resectable 7   
  Unresectable 0   
CA19.9  
  Median (pre) 58.50 Mean (pre) 927.00 
  Median (post) 29.0 Mean(post) 908.3 
  Median difference b/w pre and post -9.00 Mean difference b/w pre and post -60.18 
 Paired Wilcoxon signed-ranked test. 0.019 Paired t-test p-value 0.097 
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Figure 3.4 CTC enumeration for pre- and post-surgery cohort. a. Box plot for  pre- post- 
surgery total CTC counts b. Kaplan Meier curve for overall survival of surgery cohort. c. Kaplan 
Meier curve for recurrence free survival of surgery cohort. d. Box plot for pre- post- surgery total 
CTC counts by stage e. Kaplan Meier curve for overall survival of surgery cohort by stage f. 
Kaplan Meier curve for recurrence free survival of surgery cohort by stage 
 
3.4.4 CTC usage for treatment monitoring of patients undergoing chemotherapy 
The effect of chemotherapy on CTC counts was evaluated during the patients’ course of 
treatment. CTC counts were monitored pre-, on-, and post-chemotherapy. For the pre- and on-
chemotherapy cohort, sample collection was performed 20 days (median) prior to treatment and 
85 days (median) post-treatment for 35 pancreatic cancer patients. Box plots of the data, shown in 
Figure 3.5a, also revealed a statistically significant decrease in CTC counts during chemotherapy 
(p = 0.046, paired t-test), with a mean difference of -8. The median survival time of this cohort 
was 1.48 years. By the conclusion of this study, 13 patients had been declared deceased. For the 
pre- and post-chemotherapy cohort, sample collection was performed 13 days (median) prior to 
treatment and 51 days (median) post-treatment for 22 pancreatic cancer patients. Box plots of the 
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chemotherapy (p = 0.002, paired t-test), with a mean difference of -14. From this cohort, 7 patients 
had been declared deceased by the conclusion of this study (Figure 3.5d). Patient demographics 
for both cohorts are listed in Table 3.3 and 3.4.
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Table 3.3 Statistical analysis of pre- and post-chemotherapy cohort 
Number of patients  22    
Median Age 61    
Range Age 46 to 82    
Gender     
  Male 9 40.9   
  Female 13 59.1   
CTC collection pre-CT, median (range), days -13 (1-61)  




Median (pre) 23 Mean (pre) 25 
  Median (post) 8 Mean (post) 10 
  Median difference b/w pre and post -13 Mean difference -14 




Median (pre) 9 Mean (pre) 17 
  Median (post) 0 Mean (post) 1 
  Median difference b/w pre and post -6 Mean difference -16 




Median (pre) 8 Mean (pre) 9 
  Median (post) 6 Mean (post) 9 
  Median difference b/w pre and post 1 Mean difference 1 
 Paired Wilcoxon signed-ranked test 0.669 Paired t-test p-value 0.632 
Stage   
  Resectable 3    
  Borderline Resectable 13    
  Unresectable 1    
  Metastatic   5     
CA19.9   
 Median (pre) 472 Mean (pre)  1859 
 Median (post) 136.   Mean (post)  458 
 Median difference b/w pre and post -425 Mean difference  -1584 
 Paired Wilcoxon signed-ranked test. 0.003* Paired t-test p-value 0.080 
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Table 3.4 Statistical analysis of pre- and on-chemotherapy cohort 
Number of patients 35    
Age, median (range), years 64 (44-81)   
Gender, N (%)     
  Male 22    
  Female 13    
CTC collection pre-CT, median (range), days 20 (0-96)   




Median (pre) 13 Mean (pre) 17 
  Median (on) 5 Mean (on) 9 
  Median difference b/w pre and on -6 Mean difference -8 




Median (pre) 3 Mean (pre) 8 
  Median (on) 0 Mean (on) 1 
  Median difference b/w pre and on 0 Mean difference -6 




Median (pre) 6 Mean (pre) 11 
  Median (on) 3 Mean (on) 6 
  Median difference b/w pre and on -3 Mean difference -5 
 Paired Wilcoxon signed-ranked test 0.004* Paired t-test p-value 0.019* 
Stage  
  Resected 2    
  Resectable 4    
  Borderline Resectable 9    
  Unresectable 6    
  Metastatic 14     
CA19.9  
 Median (pre) 267 Mean (pre) 2152 
 Median (on) 110 Mean (on) 1171 
 Median difference b/w pre and on -89 Mean difference -1426 
 Paired Wilcoxon signed-ranked test. 0.028* Paired t-test p-value 0.043* 
 
 
   
70 
 
Figure 3.5 CTC enumeration for pre-/post- and pre-/on- chemotherapy cohort. a. Box plot 
for pre- on- chemotherapy total CTC counts b. Kaplan Meier curve for overall survival of pre- on- 
chemotherapy cohort. c. Box plot for pre- post- chemotherapy total CTC counts d. Kaplan Meier 
curve for overall survival of pre- post- chemotherapy cohort. 
3.4.5 CTC enumeration for pre- and post-radiotherapy cohort 
The effect of radiotherapy on CTC counts was evaluated for 12 patients. Sample collection 
was performed 135 days (median) prior to treatment and 72 days (median) post-treatment. Patient 
demographics are listed in Table 3.5. A statistically significant decrease in CTC counts was 
observed after treatment (p = 0.023, paired t-test), with a mean difference of -16, as shown in 
Figure 3.6a. The Kaplan-Meier curve for overall survival (Figure 3.6b) revealed a mean survival 























































Table 3.5 Statistical analysis of pre- and post-radiotherapy cohort 
Number of patients 12    
Age, median (range), years 59    
Gender, N (%)     
  Male 2 16.7   
  Female 10 83.3   
CTC collection pre-CT, median (range), days 135 (0-282)   




Median (pre) 15 Mean (pre) 23 
  Median (post) 6 Mean (post) 8 
  Median difference b/w pre and post -8 Mean difference -16 




Median (pre) 7 Mean (pre) 15 
  Median (post) 0 Mean (post) 1 
  Median difference b/w pre and post -4 Mean difference -13 




Median (pre) 8 Mean (pre) 10 
  Median (post) 5 Mean (post) 6 
  Median difference b/w pre and post -1 Mean difference -3 
 Paired Wilcoxon signed-ranked test 0.199 Paired t-test p-value 0.180 
Stage  
  Resected 1    
  Resectable 1    
  Borderline resectable 8    
  Unresectable 2     
CA19.9  
 Median (pre) 70 Mean (pre) 848 
 Median (post) 106 Mean (post) 647 
 Median difference b/w pre and post -30 Mean difference -223 
 Paired Wilcoxon signed-ranked test. 0.180 Paired t-test p-value 0.402 
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Figure 3.6 CTC enumeration for pre-/post-radiotherapy cohort. a. Box plot for pre- 
post- radiotherapy total CTC counts b. Kaplan Meier curve for overall survival of pre- 
post- radiotherapy cohort.  
3.4.6 Use of CTCs for predicting clinical prognosis in pancreatic cancer 
The correlation of overall survival with the decrease of CTC counts was examined 
for all treatment options. Figure 3.7a shows the Kaplan-Meier curve for the pre- and post-
surgery cohort. Of the 29 patients examined, 17 had a decrease in CTC counts. The log-
rank test p-value for these two curves was 0.536. For chemotherapy-treated patients, 
overall survival for both pre-/on- and pre-/post- categories was calculated. For the pre-/on- 
chemotherapy patients (Figure 3.7b), 24 of the 35 patients examined had a statistically 
significant decrease in CTC counts (p = 0.024, log-rank test). Figure 3.7c shows overall 
survival for the pre-/post- chemotherapy patients. Of the 22 patients examined, 18 had a 
decrease in CTC counts (p = 0.501, log-rank test). For the radiotherapy-treated patients 
(Figure 3.7d) 9 of the 12 patients examined had a decrease in CTC counts. A log-rank test 
for decrease versus non-decrease yielded a p-value of 0.127. In summary, a decrease in 
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Figure 3.7 Use of CTC for treatment response prediction. Kaplan Meier curve for 
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3.5 Discussion 
Pancreatic cancer has lowest overall survival rate among all types of cancer. One of the 
major challenges with pancreatic cancer consists its identification in early stages. The 
symptoms are vague and non-specific; commonly confused by other types of diseases. 
Once a patient is diagnosed, their treatment consists of (1) surgery, (2) chemotherapy and 
(3) radiotherapy. None of these options are curative, as they serve only to slow down the 
disease progression. Surgery is the first defense line in earlier stages of pancreatic cancer. 
However, only 15% of the patients qualify for such surgery. Even then, their survival rate 
only increases to 10-20%. Chemotherapy and radiotherapy are usually administered in 
advanced cancer stages. The efficacy of these treatments is hampered by the lack of early 
detection of pancreatic cancer. Even a synergistic approach for such three therapy options 
still results in poor prognosis for pancreatic cancer. Hence, the need of a biomarker for 
detecting and monitoring this disease is imperative.  
The Labyrinth allows the highly efficient isolation of CTCs in pancreatic cancer 
(Figure 3.1b). This technology enables the high throughput isolation of the spectrum of 
CTC subpopulations that are found in pancreatic cancer patients. One subpopulation of 
interest are the EMT-like CTCs. This subgroup is believed to be highly aggressive and 
metastatic, having the capability to be highly resistant to therapy. Its use in clinical settings 
could facilitate the application of CTCs as a biomarker for predicting and monitoring 
treatment response of such devastating disease (Figure 3.1a).  
In order to study the efficacy of CTCs as tumor biomarkers, 153 treatment naïve patient 
samples were processed and enumerated for Epithelial and EMT-like CTCs. Both 
populations were observed in most patients, where different morphologies and sizes of 
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CTCs were observed (Figure 3.3). This cohort was further stratified based on their cancer 
stage: resectable, borderline resectable, locally advanced and metastatic. As observed on 
the box plots for total CTCs, patients with borderline resectable tumors have a higher CTC 
count compared to other stages. For EMT-like CTC counts there is a consistent CTC 
number across all stages. Our results correlate with previously reported studies, where 
potential for cancer dissemination is observed even on the earlier stages151. The treatment 
naïve patient cohort displays a low 2-year survival rate of 0.248. Its stratification based on 
stages confirms the increased mortality rate observed in advanced stages. 
Currently, the effectiveness of pancreatic cancer treatment is evaluated through CT 
scans. This method poses many disadvantages including high operating costs and difficulty 
imaging the tumor location. CTCs could then serve as an improved alternative for 
monitoring treatment response. For the examination of CTCs’ use in surgery treatment, 29 
patients were processed for CTC counts at two different time points:  pre- and post- surgery. 
Results showed a significant decrease in total CTC counts in all patients. While considering 
the stage breakdown of this cohort, a higher decrease change of CTC counts was observed 
in the more advance stage (borderline resectable). This result could be explained by the 
fact that tumor size increases with stage. Smaller tumors tend to be more localized, while 
bigger tumors invade other organs.  Hence, more CTCs in the bloodstream are expected as 
tumor size increases. This trend is also observed in figure 3.2b, with higher CTC counts 
for borderline resectable stage even before surgery.  
Two cohorts were used to evaluate the efficacy of chemotherapy in pancreatic cancer 
patients: pre-/on- and pre-/post- treatment. In both cohorts, we observed a statistically 
significant decrease in CTC counts. While both cohorts were studied, pre- on- 
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chemotherapy results were considered to be clinically relevant. CTC counts for post- 
chemotherapy were not considered accurate as there were multiple reasons for which the 
treatment could have stopped. Some of the reasons include: (1) advanced tumor 
progression, (2) high toxicity, (3) completion of 6mo. treatment and (4) break of treatment. 
Our results showed that both total CTCs and EMT-like CTCs are highly responsive during 
chemotherapy and their potential use for treatment monitoring.   
The use of CTC counts was also evaluated across twelve patients who have undergone 
radiotherapy treatment. As shown for the other treatments, there was a significant decrease 
in CTC counts after radiotherapy was completed. Among the three treatments, this cohort 
showed the biggest decrease in total CTC counts.  
Previous studies on breast and prostate cancer have shown the utility of CTCs as a 
biomarker for predicting overall survival in cancer patients 120,161,164. Consistent with these 
studies, our results showed that patients with a decrease in CTC counts have a higher 
overall survival than patients with increasing or constant CTC counts. While this trend was 
observed in all treatment options, a significant p-value was obtained only on the pre-/on- 
chemotherapy cohort. Because chemotherapy is the most commonly treatment used, our 
findings highlights the potential of CTCs as a biomarker for predicting overall survival in 
pancreatic cancer. CTCs can open the opportunity for developing personalized medicine 





CHAPTER 4. HETEROGENEITY STUDIES FOR THE 
CHARACTERIZATION OF PANCREATIC CTCs ISOLATED FROM 
PANCREATIC DUCTAL ADENOCARCINOMA (PDA) PATIENTS 
 
4.1 Abstract 
New methods for detection and characterization of circulating tumor cells (CTCs) in 
the blood are poised to have a significant impact in clinical medicine. An important issue 
in the monitoring of CTCs is that there may be substantial heterogeneity with several sub-
populations denoted by different cell surface marker proteins. Although EpCAM has been 
used to identify and isolate CTCs from blood, CTCs may transition to a mesenchymal form, 
which does not have this marker, and these cells may form the majority of the CTCs 
present. We have thus employed the use of the Labyrinth for CTC isolation, which exploits 
inertial forces to differentially focus live cells for separation. The CTCs were separated 
from whole blood from pancreatic cancer patients and were collected on a slide for 
fluorescence detection. These cells were monitored for circulating cells with markers 
associated with the cancer stem cell population including CK, CD24 and CD90 and that 
were CD45-. We found that there were cells that were CK+ which denotes the marker for 
CTCs that also had CSC markers associated with them in most cases. We also found that 
there were a substantial number of cells collected that had multiple markers associated with 
CSCs. Tissue analysis from one of the patients showed cells co-expressing CK and CD90, 
as well as for CD24 and CD90 combination. This work demonstrates the use of new 
technology for identifying circulating cells without EpCAM and that have unique 
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4.2 Introduction  
Circulating tumor cells (CTCs) are critical to understanding the biological process 
of metastasis and could serve as a potential biomarker to noninvasively evaluate tumor 
progression and response to treatment. It has been extensively shown that CTCs released 
from the primary tumor travel through the blood to distant anatomic sites leading to lethal 
metastasis4. Therefore, these cells could be a good surrogate biomarker for prognosis, as 
well as detection and monitoring of the disease24. To date, limited data has been collected 
regarding the numbers of these cells in the bloodstream at different stages of cancer and in 
different types of cancer, their molecular and biological heterogeneity, and their 
significance in the natural history of the disease4. CTCs hold the potential to serve as a 
‘liquid biopsy’ for cancer patients 7,8. CTCs can be detected from peripheral blood of 
patients and hold the promise of being a real-time biomarker for cancer detection and 
management. The utility of CTCs as a predictive and prognostic marker has been explored 
in various cancers like pancreatic cancer, breast cancer, prostate cancer, liver cancer and 
colorectal cancer19-21. 
CTCs have been detected and studied in patients with pancreatic adenocarcinoma165.  
Although evidence showed that the presence of CTCs is associated with poor outcome3, 
several studies suggested that relatively low levels of CTCs can be detected in most 
pancreatic cancer patients compared to other types of malignancies28. The inability of 
current widely used technologies to detect CTCs due to their low sensitivity poses a 
potential barrier for their use as an effective biomarker. 
The detection and characterization of CTCs is a challenging problem for several 
reasons including the very small numbers of these cells in the bloodstream and their 
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heterogeneity. CTCs are typically observed at a concentration of 5-20 cells per 7.5 mL 
whole blood, even in advanced stage cancers, compared to millions of white blood cells 
and even larger numbers of red blood cells127,166-168. A method with high separation 
capabilities and throughput is needed to collect an isolated population of CTCs in sufficient 
numbers for further analysis. The second issue is the heterogeneity of CTCs as multiple 
sub-populations may exist, which have the same genetic basis but a different phenotype 
due to heterogeneity within the primary tumor. These different sub-populations may have 
different roles in metastatic progression and thus need to be monitored based on their single 
cell content. A method which can detect these sub-populations and their relative 
populations will be essential in determining cancer prognosis and selecting appropriate 
therapies169-171. 
The standard approach for isolation of CTCs involves methods based on immuno-
affinity with antibodies specific for CTC surface proteins that are not present on other 
blood cells172. This strategy has generally employed EpCAM as a surface marker for CTCs. 
However, many CTCs do not express EpCAM especially after these cells undergo 
epithelial to mesenchymal transition (EMT) where EpCAM is significantly down-
regulated169. Alternative approaches have used label free isolation methods based on the 
physical properties of the cells24,173,174. Tumor cells derived from solid tumors are larger 
compared to most blood cells. Size based filtration techniques have been developed in 
which cells are separated on filters or through pores in membranes175. These methods are 
subject to problems with clogging and the amount of sample that can be processed without 
sacrificing yield and purity is limited.  
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More recently the Nagrath laboratory has developed a method for CTC enrichment 
using micro-chip technology to separate CTCs from the peripheral blood of cancer patients. 
This device utilizes inertial forces and is capable of continuous, selective, high-throughput 
separations without the use of antibodies. The device, termed Labyrinth, structure 
incorporating a curved path in which cells can be separated from whole blood at a rate of 
2.5mL/min through hydrodynamic focusing based on size91. The isolated cells remain 
viable after processing for further analysis. Additionally, this method can separate out 
CTCs from other cells in the blood regardless of their surface markers. This device 
facilitates heterogeneity studies to understand the variability of surface marker expression 
on CTCs. 
It has long been appreciated that tumors are composed of heterogeneous 
populations of cells. To date, limited data has been collected regarding the numbers of 
these cells in the blood stream at different stages of cancer and in different types of cancer, 
their molecular and biological heterogeneity, and their significance in the natural history 
of the disease4. EMT and stem cell phenotypes are highly enriched in CTCs5  and the 
phenotype of CTCs was established as a stronger predictor of outcome than sole 
enumeration of CTCs in a defined volume of blood. One of the potential EMT markers for 
CTCs in pancreatic cancer is CD90, also known as Thy-1. This marker is a heavily 
glycosylated, glycophosphatidylinositol (GPI)-anchored cell surface protein that has been 
shown to be a cancer stem cell indicator in different types of cancer176. In pancreatic cancer, 
Zhu et al. reported high levels of CD90 in cancer-associated fibroblast surrounding the 
tumor cells177. In addition, s CD90+ cells were found clustered around CD24+ malignant 
ducts, indicating that CD90 could play a role in the tumor-stroma interactions and in 
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cancer-associated fibroblasts that could potentially assist in pancreatic tumorigenesis and 
development177. 
This work utilized the Labyrinth for the isolation of CTC populations from whole 
blood of pancreatic cancer patients (n=12). These isolated CTCs will be monitored for 
markers associated with the cancer stem cell population including CD24, CD90 and that 
are CD45-. These cells are also known as circulating tumor stem cells(CTSCs)178. These 
combinations are rare in tissues but are shown to be observed in cells circulating in the 
bloodstream including the markers CD24/CD90. This work demonstrates the use of the 
Labyrinth for identifying circulating cells without EpCAM and that have unique 
combinations of CSC markers that potentially could be used for prognosis and monitoring 
therapies in pancreatic cancer. We also show that there is extensive heterogeneity for CK+ 
cells for these CSC markers for both intra-patient and interpatient comparisons. 
4.3 Methods 
4.3.1 Patient Sample Processing 
Labyrinth is pre-flowed with 1% Pluronic acid solution (diluted in 1X PBS) at 100 
µL/min for 10 minutes to prevent cell clotting on channel walls. RBCs in blood samples 
were removed using density separation (6% dextran solution, M.W. 250,000) prior to the 
Labyrinth process. The blood sample with dextran solution was kept still in room 
temperature for 1 hour to bring down the RBCs driven by density difference. The 
supernatant, which includes everything in whole blood except RBCs, was carefully taken 
out using pipets, and was diluted with PBS buffer at a 1:3 ratio. Blood samples were then 
processed through the device, at a flow rate of 2 mL/min. Patient demographics are found 
on Appendix C.1. 
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4.3.2 Preparation of Cytospin slides 
Second outlet product is processed using Thermo Scientific™ Cytospin 4 
Cytocentrifuge. 300 µL of sample is inserted into each cytospin funnel and cytocentrifuged 
at a speed of 800 rpm for 10 minutes. Samples are fixes on the cytoslides using 4% PFA 
and cytocentrifuged at the same conditions described above. Cytoslides are stored at 4o C 
for further staining.    
4.3.3 Immunostaining protocol of cytoslides 
Samples were permeabilized by applying 0.05% PBST solution for 15 minutes. 
Slides were then blocked using 20% donkey serum for 30 min at room temperature (RT). 
A cocktail of primary antibodies were added and left in a humidified chamber overnight.  
Next day, cytoslides were washed thrice with 0.05% PBST for 5 minutes. Samples were 
incubated in dark with secondary antibodies for 45 minutes at RT. Finally, samples were 
washed thrice with 0.05% PBST for 5 minutes and mounted with Prolong Gold with DAPI. 
List of antibodies used can be found on Table 4.1. 
Table 4.4.1 List of antibodies used in this study 
Primary Antibody Source-Reactivity Company (Cat No.) Concentration 
CD24 Mouse IgG1-Human Abcam (ab76514) 1:500 
CD90 Rabbit IgG-Human Abcam (ab9257) 1:500 
CD133 Mouse IgG2aκ-Human 
Emd Millipore  
(MAB4399) 
1:500 
CK-19 Rabbit IgG- Human Santa Cruz (sc- 25724) 1:500 
CK-19 Mouse IgG- Human Santa Cruz (sc-6278) 1:500 
CD45 Rat IgG2b- Human Santa Cruz (sc-70699) 1:500 
PanCK Mouse IgG1- Human Biolegend (628602) 1:500 
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PanCK Rabbit IgG- Human Abcam (ab9377) 1:500 
SecondaryAntibody Source-Reactivity Company (Cat No.) Concentration 
Alexa Fluor® 488 Donkey-Rat IgG Invitrogen™ (A21208) 1:500 
Alexa Fluor® 568 Donkey-Rabbit IgG Invitrogen™ (A10042) 1:500 
Alexa Fluor® 647 Donkey-Mouse IgG Invitrogen™ (A31571) 1:500 
Alexa Fluor® 546 Goat-Mouse IgG2a Invitrogen™  (A21133) 1:500 
Alexa Fluor® 647 Goat-Rabbit IgG Invitrogen™  (A21244) 1:500 
Alexa Fluor® 647 Goat-Mouse IgG1 Invitrogen™  (A-21240) 1:500 
 
4.3.4 Double Fluorescent Immunohistochemistry 
The FFPE tissue slides were dewaxed in xylene for 10 min twice and then 
rehydrated through a series of alcohol solutions (100% ethanol twice, 95% ethanol, 75% 
ethanol) to water. Antigen retrieval was achieved by boiling the slides in citrate buffer at 
pH 6.0 (Invitrogen) for 15 min. The slides were incubated with 2% BSA in PBST for 1 hr 
at room temperature to block non-specific binding. To achieve double fluorescent 
immunostaining, a mixture of rabbit anti-human CD90 antibody (1:100, Abcam, 
Cambridge, MA) with mouse anti-human CD24 antibody (1:100, Abcam, Cambridge, MA) 
or mouse anti-human CK antibodies which included CK19 antibody (1:100, Santa Cruz) 
and PanCK antibody (1:200, Biolegend) was incubated with the slides, respectively, 
overnight at 4 ºC. Then DyLight 488 anti-rabbit IgG and DyLight 549 anti-mouse IgG 
antibodies (Vector laboratories, Burlingame, CA) were diluted (1:150) and incubated with 
the slides for 1 hr at room temperature. There were three washes of PBST between each 
step. DAPI (1:8000, Sigma) was then incubated with the slides to visualize nuclei. Finally, 
the slides were dehydrated in alcohol (75%, 95% and 100% ethanol), cleared in xylene and 
 
   
85 
then coverslipped using a mounting medium (Sigma). The staining was evaluated under an 
Olympus BX-51 fluorescent microscope where CD90 staining was shown in green, CD24 
or CK in red, and DAPI in blue. 
4.4 Results  
The Labyrinth is a label free technology that facilitates the study of the phenotypic 
heterogeneity among CTCs, which remains elusive because platforms that capture CTCs 
are not comprehensive. EpCAM− CTCs are crucial to understanding cancer metastasis, 
with the ultimate goal of developing treatments to prolong patient survival176. Furthermore, 
the fraction of CTCs that extravasate and are able to generate distant metastases may have 
lost EpCAM expression and are believed to have undergone the epithelial-mesenchymal 
transition (EMT), which results in the downregulation of epithelial cell markers14,177-179. In 
fact, several groups have also reported that CTCs express stem cell and/or EMT-associated 
markers179. This study examines the use of CD90 as an EMT marker and its co expression 
with epithelial markers CK and CD24, as observed on Figure 4.1.  
In order to isolate and analyze protein expression of epithelial and mesenchymal 
markers in CTCs, 12 blood samples from pancreatic cancer patients were processed 
through Labyrinth (Figure 4.1). These samples were classified according to their stage: 
resectable (n=4), unresectable (n=4) and metastatic (n=4). CTC were recovered from the 
second outlet from each patient. Once isolation was completed, the potential of CTCs as a 
surrogate for tissue biopsies using immunocytochemistry was studied to analyze protein 
expression of epithelial and mesenchymal markers. 
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CTCs were firstly enumerated using the standard definition of a CTC, in which they 
are identified as DAPI-positive nucleated cells (shown in blue) staining positive for 
cytokeratin (shown in red) and negative for CD45 (shown in green), as shown on Figure 
4.2. Using this criteria, it was observed that all pancreatic cancer patient samples tested 
positive for CTCs. Results showed an average yield of 10±7 CTCs per mL blood for cancer 
patients; while healthy controls showed 1±0.6 CTCs per mL blood. Although a more 
extensive cohort is needed for statistical significant results, there is a higher average CTC 























Figure 4.1 Experimental outline for coexpression studies on isolated CTCs a) 
Schematic showing the experimental procedure for this study. Once CTCs are isolated they 
are characterized using Epithelial and EMT-like antibodies. b) When patient sample is 
processed through the device, cell are isolated based on their size. WBCs are discarded 
from the first outlet, while CTCs are collected on the second outlet. c) SEM image of loops 
and turns inside the Labyrinth. 
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Co-expression for CK and CD90 was analyzed for previously mentioned patient 
samples. Among the isolated CTCs for each patient, Figure 4.3 shows that all analyzed 
patient samples exhibit CTCs that co-express CK and CD90. Furthermore, more than 50% 
of CTCs across all patients showed this co-expression pattern, suggesting higher number 
of EMT-like cells than for the epithelial phenotype (CK+). No significant difference in co-
expression patterns was observed across different cancer stages. This could suggest that 
EMT-like cells are present in early stages of pancreatic cancer, highlighting that this 



























































Figure 4.2 CTC counts for pancreatic cancer patient samples. a) Twelve patients from 
different cancer stages were analyzed for CTC counts. CTCs are defined as CK+ (red), 
CD45- (green) and DAPI+ (blue) b) Immunofluorescent images of CTCs and WBCs. 
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To study the potential of other markers as a tool for identifying early stages of 
cancer we used the markers CD24 and CD90. CD24 was used as a stem-like marker; while 
CD90 was used as an EMT marker. Figure 4.4 demonstrates the high variability of marker 
expression CD24+/CD90+ cells across all patients. Most of these patients exhibit a high 
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Figure 4.3 Coexpression enumeration for CD90 and CK in CTCs 
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Double fluorescence IHC staining was performed to investigate the co-expression 
of CD90 with CD24 or cytokeratin (CK) in pancreatic adenocarcinoma tissue.  Figures 4.5 
and 6 showed the overlap between CD90 (green) and CK/CD24 (red), respectively, in a 
patient with PDAC at stage IIA. As shown in Figure 4.5, CK (red) was strongly and 
abundantly expressed in the cytoplasm and membrane of malignant epithelial cells in 
PDAC. A small overlap between CD90 and CK (shown as yellow or orange in Figure 4.5) 
was localized on the cell surface of malignant ductal cells (indicated with arrows in Figure 
4.5a) or in the cytoplasm of tumor cells (marked with squares in Figure 4.5b). As shown in 
Figure 4.6a, the overlap of CD90 and CD24 (indicated by rectangles) was observed in both 




















































Figure 4.4 Coexpression of CD24 and CD90 on blood cells. a) Quantification of CD24 
and Cd90 coexpression  b) Immunofluorescent images showing coexpression of CD24 
(pink) and CD90 (red) on DAPI+ (blue) cells. 
 




Figure 4.5 Representative images of double fluorescent immunostaining of CD90 
(green) and CK (red) in a patient specimen of PDAC at stage IIA. DAPI counterstaining 
was used to visualize nuclei (blue). The co-expression of CD90 and CK was shown in 
yellow or orange in the merged images. a) Overlap of CD90 and CK on the cell surface of 
malignant ductal cells (indicated with arrows). b) Co-localization of CD90 and CK in the 
cytoplasm of tumor cells (marked with squares). Scale bars = 50 µm. 
 






Figure 4.6 Double fluorescent immunostaining of CD90 (green) and 
CD24 (red) in pancreatic adenocarcinoma. DAPI counterstaining was 
used to visualize nuclei (blue). The co-expression of CD90 and CD24 was 
observed in endothelial cells of vessels (Figure 6a, scale bars = 100 µm) 
and malignant tumor cells (Figure 6b, scale bars = 50 µm) in PDAC. 
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4.5 Discussion 
Consistent with previous studies178, CD24 exhibited a strong or moderate 
expression predominantly on the membrane and cytoplasm of malignant ducts and vessels 
in PDAC, while the overexpression of CD90 was observed in the tumor vasculature of 
PDAC. In a previous study, Foygel et al. reported that CD90 could serve as a target for 
PDAC neovasculature imaging due to its significantly increased expression in PDAC 
vessels179. The co-localization of CD90 and CD24 on endothelial cells in tumor vasculature 
of PDAC indicates that CD90 may play a role in angiogenesis in pancreatic 
adenocarcinoma and these endothelial CD90+CD24+ cells may escape from primary 
tumors and invade into the blood circulation as CTCs.   
The expression of cells with the CD24+/CD90+ combination of markers is 
relatively rare in the tissues and is only found in approximately 1% in the tissue examined. 
In early stage cancers these cells with this combination of markers are rarely if ever 
observed in pancreatic cancer tissues178. The CD24 generally stains in the ducts while 
CD90 stains outside the ducts on the stellate cells in the stroma. The fact that there are a 
relatively large percentage of the CTCs, which are circulating with both markers, may be 
significant. This type of phenomenon has been observed in previous work where CTCs 
may be arrested in a biphenotypic state14  where CTCS may still express epithelial markers 
along with mesenchymal markers during EMT. These cells may be involved in bringing 
the properties of both types of cells to promote metastasis where tumor stromal signaling 
in priming cancer cells to metastasize is an essential process. 
Another important issue is that these CK+ CTCs have a distribution of CSC markers 
associated with them. There is a broad heterogeneity of CSC markers even within the same 
patient where some cells may have one or another or both of the markers associated with 
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them. This heterogeneity becomes even more apparent when the comparison is made 
between patients where there are different distributions of these markers. This 
heterogeneity has only been studied herein for the CD24 and CD90, however the 
heterogeneity is likely to be even more complex where there are other CSC markers that 
are not being considered such as CD133 for example. These different markers and their 
combinations probably represent cells with different functions or properties that may be 
related to metastasis and the ability to escape the immune system for example. 
In summary, we have used a label free method to isolate CTCs from the blood of 
pancreatic cancer patients where using CK+ as a marker we could typically identify 10-30 
CTCs/mL. Moreover, we could identify the presence of the surface markers of CD24 and 
CD90 on these CK+ cells. The large majority of CK+ cells were also found to be CD90+ 
where CD90 is a marker of stromal cells in pancreatic cancer and is associated with EMT. 
We also found a mixed population of CK+ cells in the blood which were CD24+CD90+. 
A staining of the tissues showed that these CD24+CD90+ cells are very rare making up 
1% of the total population whereas in the blood they constitute over 50% of the CTCs in 
many of the samples. These cells appear to have a mixed epithelial/stromal composition 
where it is postulated that these cells have enhanced survival properties in the bloodstream 
and may be important in cancer progression and metastasis. Future work will involve 
further isolation of these cells for investigation as to their metastatic properties and their 
transcriptomic and proteomic expression. 
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CHAPTER 5. EXPANSION AND FUNCTIONAL CHARACTERIZATION 
OF PANCREATIC CTCs FROM IN VITRO AND IN VIVO MODELS 
 
5.1 Abstract 
Improvement in pancreatic cancer treatment represents an urgent medical goal that 
has been hampered by the lack of predictive and biomarkers. Circulating Tumor Cells 
(CTCs) may be able to overcome this issue by allowing the monitoring of therapeutic 
response and tumor aggressiveness through ex vivo expansion. The successful expansion 
of CTCs is challenging due to low number in blood and the high contamination of blood 
cells. Here, we explored the utility of pancreatic CTC cultures as a preclinical model for 
treatment response. CTCs were isolated from ten locally advanced pancreatic cancer 
patients disease using the Labyrinth device and expanded three CTC samples in adherent 
and spheroid cultures. Proliferation and CTC phenotype were evaluated in culture and 
compared to the original patient specimen. Additionally, we evaluated take rate and 
metastatic potential in vivo and examined the utility of CTC lines for cytotoxicity assays. 
Our results demonstrate that CTC cultures are possible and provide a valuable resource for 
translational pancreatic cancer research while also providing meaningful insight into the 
development of treatment resistances and distant metastasis. 
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5.2 Introduction  
Pancreatic cancer is the third leading cause of cancer-related death in the United 
States180. In fact, its survival probability has not improved substantially over nearly 40 
years1,180. While surgical removal of the tumor represents the best treatment option for 
pancreatic cancer patients, only 20% of patients qualify for surgery1,181. Chemotherapy or 
chemotherapy combined with radiation is typically offered to patients with locally 
advanced disease181,182. 
A major challenge in the management of these patients is the early assessment of 
response to therapy that would allow the selection of the appropriate therapy and limit 
toxicity in treatment-resistant patients. Computed tomography (CT) is routinely used to 
stage and reassess patients following treatment. However, a number of studies have 
demonstrated that CT-detected treatment responses are infrequent183. Obtaining tissue from 
pancreatic cancer patients with locally advanced disease for histological diagnosis and 
acquiring pre- and post-monitoring presents a substantial challenge.  
Over the past few years, several studies have studied circulating tumor cells (CTCs) 
in many epithelial cancers and suggested that CTCs can be used as clinical biomarkers of 
treatment response and prognosis3,4,23,120,127,158,161. CTCs are cancer cells that have shed 
into the vasculature or lymphatics from a primary tumor and are carried around the body 
in the circulation. CTCs are believed to have the potential to develop into distant 
metastases, which are the major cause of cancer related mortality. However, the isolation 
of viable CTCs is an actively research area with limited success. Hence, the dire need of 
such technologies hamper culture approaches.  
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The current gold standard for CTC isolation is the CellSearch system, which uses 
magnetic beads functionalized with antibodies against the epithelial cellular adhesion 
molecule (EpCAM)3,22,30. Due to the use of antibodies for CTC capture, this system fails 
to detect cancer cells with reduced EpCAM expression and may thus only enrich a small 
subpopulation of CTC 20,40,184,185. Hence, to address the shortcomings of the FDA-approved 
CellSearch system, the development of new technologies with higher sensitivity is desired. 
This can be overcome by the use of microfluidic technologies that allow for unprecedented 
spatio-temporal control of cells 4. Their application in cancer research is now well 
established186 with a number of studies demonstrating successful isolation and 
characterization of CTCs from clinical samples133. Microfluidic CTC isolation 
technologies are mainly categorized by their exploitation of either CTCs’ distinctive (i) 
biological properties or (ii) physical properties186. The former is based on the expression 
of cell surface markers, while the latter includes size, deformability, density, and electric 
charge187. The use of CTCs’ physical properties to develop microfluidic devices allows 
label-free isolation, which overcomes biased cell selection using the CTCs’ biological 
properties, such as protein expression and molecular markers. Furthermore, isolated cells 
using label-free technology are not modified, which permits greater flexibility for 
downstream characterization of CTCs. In summary, advances in label free microfluidic 
technologies allow the reliable detection and isolation of CTCs from clinically available 
blood draws. This will in turn allows functional characterization of CTCs to understand the 
utility of CTCs as predictive and prognostic markers and may serve as a surrogate tumor 
biopsy. However, previously reported clinical studies have mostly focused on CTC 
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enumeration in guiding prognosis in metastatic cancer patients, and current research is 
exploring the pharmacodynamic and predictive biomarker utility of CTCs. 
A number of studies have isolated and evaluated CTCs in patients with pancreatic 
adenocarcinoma188. Early studies identified CTCs in pancreatic cancer patients with 
metastatic disease using several tumor cell markers including CK20, CEA, and c-MET and 
demonstrated that compared to other types of malignancies, these patients have relatively 
low numbers of CTCs189-193. Recent reports have concentrated on CTCs in patients with 
locally advanced pancreatic cancer. Ren et al. examined CTCs in 31 patients with stage III 
and nine patients with stage IV pancreatic cancer.  Eighty percent of these patients were 
found to have CTCs prior to chemotherapy, and this number decreased to 29% after 
treatment194. Bidard et al. analyzed blood samples of 79 patients with locally advanced 
pancreatic cancer treated on a clinical trial for CTC detection.  This study identified CTCs 
in only 11% of patients; however, the presence of CTCs was associated with poor 
outcome3.  
Beyond CTC enumeration, an ex vivo expansion and functional characterization of 
patient-derived CTCs will help to elucidate the clinical application of CTCs in pancreatic 
cancer. Due to their low frequency in pancreatic cancer patients188 expanding such cells 
becomes a dire need of any CTC study. To our knowledge, no CTC cultures in pancreatic 
cancer have been reported. However, some success has been reported across other types of 
cancers using affinity based approaches.  In breast cancer, CTC cultures were reported by 
Yu et al. using the CTC-iChip115. Cultures were done under hypoxic and nonadherent non-
adherent culture conditions, achieving success for 6/36 breast samples. In colon cancer, 
Cayrefourcq et al. was also able to expand CTCs from 2/71 colon cancer patients116. Our 
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own research group reported CTC culture in lung cancer using a microfluidic co-culture 
device, where 14 out of 19 samples were expanded64. While these technologies have shown 
the ability to expand CTCs, the inherent biased CTC selection of immunoaffinity based 
technologies limits the ex vivo functionality study of all distinct subpopulations of CTCs.  
In order to further validate the utility of expanded CTCs, researchers have started 
developing CTC-derived xenografts (CDX) models. Such models serve as a method to 
examine expanded CTCs’ in vivo properties including tumorigenicity and drug 
susceptibility. For example, Cayrefourcq et al. showed the generation of colon tumors from 
a CTC-derived cell line in immunodefficient mice116. In breast cancer, Yu et al. 
successfully established  five CTC cell lines, where three were tumorigenic in mice115. In 
small-cell lung cancer, Hodgkinson et al. demonstrated that CTCs from patients with either 
chemosensitive or chemorefractory tumors are tumorigenic in immune-compromised mice. 
Furthermore, their findings mirrored the donor patient's response to platinum and etoposide 
chemotherapy114. In order to successfully perform these in vivo CTCs studies, a high initial 
concentration of CTCs was required (>106 cells) for all studies, making CTC expansion 
essential.   
Recently, we developed and optimized a microfluidic device, the “Labyrinth”, for 
the high throughput label free isolation of CTCs, which takes a hydrodynamic approach 
for the size based isolation of CTCs (Chapter 2). The Labyrinth is an inertial microfluidics 
based separation technology that demonstrated greater than 90% recovery when tested with 
various cell lines including pancreatic cancer cell lines, while achieving an 89% WBC 
removal. In our approach, since no positive or negative selection of cells is needed, the 
Labyrinth enables the study of CTC heterogeneity and allows the identification of multiple 
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CTC subpopulations through further downstream biological and functional studies. Our 
previous study showed the presence of CTCs that have undergone the epithelial-to-
mesenchymal transition (EMT) across all pancreatic cancer patients. The use of our label 
free Labyrinth device enables the study on viable EMT-like CTCs, which are believed to 
be the most aggressive subtype of CTCs151,195,196. Building upon our previous expansion 
work on lung cancer, this study uses the Labyrinth to expand CTCs using a monoculture 
approach to maintain the simplicity of the Labyrinth by eliminating the need of CTC 
purification from other cell lines. 
In the present study we explore the utility of pancreatic CTC cultures as a preclinical 
model for treatment response.  CTCs were isolated from the blood of pancreatic cancer 
patients with locally advanced disease using the Labyrinth and expanded in vitro. CTC 
cultures were then characterized in both 2D (adherent) and 3D (spheroid) conditions. Such 
characterization was performed through the examination for epithelial and EMT features 
and compared to the original patient specimen. Furthermore, we evaluated tumorigenicity 
in vivo by injecting cultured CTCs into a NOD/SCID mice, thus creating a pancreatic CDX 
model. To our knowledge, these are the first ever pancreatic CTC cultures developed from 
pancreatic patient samples. The isolation and expansion of CTCs can provide meaningful 
information to elucidate the process of pancreatic tumorigenesis and dissemination to 




10 ml of whole blood for CTC extraction was obtained from ten patients with 
locally advanced pancreatic cancer as part of an Institutional Review Board approved 
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protocol (HUM00085016). Informed consent was obtained from all participating patients. 
Patient Demographics are shown on appendix table D.1. 
5.3.2 CTC isolation using Double Labyrinth  
For patient samples, red blood cells were removed from the samples using density 
separation (6% dextran solution, M.W. 250,000) prior to the labyrinth. The sample-dextran 
solution was kept still in room temperature (RT) for 1h to sediment the red blood cells. The 
supernatant was removed and diluted with PBS buffer at a 1:3 ratio. Samples were then 
processed through the pre-flowed labyrinth, at a flow rate of 2.5mL/min. To achieve higher 
purity all the second outlet product for all samples were diluted 1:2 samples and run 
through another labyrinth. The purified CTCs were used for characterization by 
immunofluorescence and culture. 
5.3.3 CTC culture 
The second outlet was processed using a RBC lysis buffer at a 2:1 (buffer:sample) 
and incubated on ice for 3min. Samples were then spun down and the pellet resuspended 
in culture medium (RPMI1640) supplemented with 10% FBS and 1% antibiotics. For 
adhered cultures, the cell suspension was plated into fibronectin coated 24 well plates. For 
spheroid cultures, CTCs were seeded on hanging drop array plates with 10cells/drop using 
serum supplemented RPMI. Confocal microscopy for live/dead staining using calcein and 
ethidium homodimer at Day 14, indicate high viability within CTC spheroids. 
For growth curve analysis, CTC cultures were seeded in 96 well dishes at 1000 cells per 
well. Cell proliferation was evaluated using Alamar blue per the manufacture’s guidelines 
for 6 days. Absorption was measured using the Biotek-Synergy Neo-Plate reader. 
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5.3.4 Immunofluorescence staining  
CTCs were processed using Thermo Scientific™ Cytospin 4 Cytocentrifuge according to 
the manufactures guidelines. Cytoslides were fixed using 4% PFA and stored at 4°C until 
staining.    
For immunostainings, samples were permeabilized with 0.05% PBST solution for 15min 
and blocked using 20% donkey serum for 30min at RT. A cocktail of primary antibodies 
was added and incubated at 4°C in a humidified chamber overnight. Samples were 
incubated in dark with secondary antibodies for 45min at RT and mounted with Prolong 
Gold () with DAPI. CTCs were classified PanCK and DAPI positive and CD45 negative. 
White blood cells (WBC) were considered to be CD45 and DAPI positive. 
Slides with spheroid sections were deparaffinized and rehydrated by dipping three 
times in xylene, two times in 100% ethanol and once each in 95% and 70% ethanol. 
Antigen retrieval was performed by boiling slides in citrate buffer (pH=6.0) for 10min. 
Chamber slides with cultured cells were fixed with 4% Paraformaldehyde (Electron 
Microscopy Sciences) for 10min and then washed with PBS. Samples were then 
permeabilized with ice-cold 1:1 Methanol:Acetone for 1min and washed with PBS. 
Blocking buffer consisting of 5% goat serum (Sigma Aldrich) diluted in PBS was applied 
at room temperature for 30min to prevent non-specific adhesion. Monoclonal anti-vimentin 
(5µg/ml, Thermo Fisher: MA1-10459) was diluted in blocking buffer and applied to 
samples overnight at 4oC. Samples were washed 3 times for 5minwith PBS. Goat anti-
mouse IgM CF770 (4µg/ml, Biotium: 20385), anti-Pan-Keratin Alexa Fluor 555 
(0.64µg/ml Cell Signaling Technology: 3478S), anti-EpCAM APC (0.24µg/ml BD 
Biosciences: 347200), anti-CD44 BV510 (1µg/ml, BioLegend: 103043), and anti-CD45 
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FITC (1µg/ml, BioLegend: 304005) were diluted in blocking buffer and applied to samples 
overnight in a refrigerator at 4oC. Samples were again washed 3 times for 5min with PBS. 
DAPI (1µg/ml, Thermo Fisher) diluted in PBS was applied for 10min at room temperature 
to label nuclei. A drop of Prolong® Diamond Antifade Mountant (Thermo Fisher) was 
then added and coverslips were mounted onto the slides for imaging. 
5.3.5 Flow cytometry 
Cells were trypsinized, washed with ice-cold PBS, and fixed at a concentration of 
2 × 106 cells/ml in ice-cold 70% ethanol. For γH2AX analysis, samples were incubated 
with a mouse anti–γH2AX-specific antibody (clone JBW301; Millipore) overnight at 4°C 
followed by incubation with a fluorescein isothiocyanate–conjugated secondary antibody 
(Sigma) as previously described [33]. For quantification of γH2AX positivity, a gate was 
arbitrarily set on the control, untreated sample to define a region of positive staining for 
γH2AX of approximately 5%. This gate was then overlaid on the treated samples. Samples 
were stained with propidium iodide to measure total DNA content and analyzed on a 
FACScan flow cytometer (Becton Dickinson) with FlowJo software (Tree Star). 
5.3.6 Immunohistochemistry 
Xenograft tumors were excised, fixed and paraffin embedded. Paraffin tissue 
sections were cut, dried and dewaxed. Endogenous peroxidase was blocked in 3% 
hydrogen peroxide for 10 min. Microwave antigen retrieval was carried out under pressure 
at 120C for 10 min in 10 mM Citrate buffer, pH 6.0 using a T/T Mega microwave oven. 
Endogenous biotin was blocked in Vector’s biotin blocking kit, and then slides were 
labeled with primary antibodies to cytokeratin (DAKO, Glostrup, Denmark, AE1/AE3, 
1:200) and Smad4 overnight. Biotinylated anti-mouse IgG incubations were carried out 
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followed by streptavidin biotin detection system (Signet Pathology System, Deham, MA, 
USA) for 30min each Immunoreactivities were revealed by incubation in Nova Red 
substrate (Vector Lab, Burlingame, CA, USA) for 5min and counterstained in Mayer’s 
haematoxylin. 
5.3.7 Cell Proliferation Assay 
Cultured cells were seeded at a concentration of 500 cells/well in 100µL of RPMI 
media into 96 well plates. Cells were incubated from 1-6 days at 37ºC and 5% CO2. 
10µL/well Cell Proliferation Reagent WST-1 (Roche) was added and incubated for 1h and. 
Plate shaken for 1min on a shaker. The absorbance was measured at an emission 
wavelength of 450nm, using a BioTek-Synergy Neo multi-purpose plate reader. 
5.3.8 Treatments 
Cultured cells were seeded at a concentration of 1000 cells/well in 100 µL of RPMI 
media into 96 well plates. Cells were incubated for 24h at 37ºC and 5% CO2. Media was 
exchanged for Gemcitabine (0, 0.05 0.1, 0.5, 1, 5 uM)  or 5-FU (0, 1, 5, 10, 50, 100 uM) 
diluted on RPMI media. Cells were incubated for 24h, the media was replaced and cells 
cultured for 48h. 10µL/well Cell Proliferation Reagent WST-1 (Roche) was added and 
incubated for 1h. Plate was then shake for 1min on a shaker. The absorbance was measured 
at an emission wavelength of 450nm, using a BioTek-Synergy Neo multi-purpose plate 
reader. 
For radiation treatments, cells were treated with a single dose of 4Gy at 60% 
confluency and fixed for flow cytometry 16h after treatment. For gemcitabine treatments, 
cells were treated with 100nM gemcitabine for 2h and fixed for flow cytometry 22h after 
treatment. 
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5.3.9 Xenografts 
Animal experiments were carried out using protocols approved by the University 
Animal Care Committee (PRO00006457) under the guidelines of the Association for 
Assessment and Accreditation of Laboratory Animal Care.  
For CTC xenografts, 106 cells were injected subcutaneously into the flank of 4-5 
week old NOD/SCID mice. Tumors were grown until the humane endpoint of ~1cm in 
diameter or distress due to ascites or metastasis. Tumor size was evaluated twice a week 
using calipers. 
5.3.10 STR Fingerprinting  
The UM DNA Sequencing Core performed cell identity verification using the 
Applied Biosystems IdentifilerPlus kit to assess CODIS markers. DNA testing was 
performed according to manufacturer’s recommended protocols. Resulting fragments were 
assessed on an ABI 3730XL Genetic Analyzer. Analysis of resulting electropherograms 
were performed using ABI GeneMapper V5.0 software, as per manufacturer’s 
recommended protocols. 
5.4 Results  
5.4.1 Patients 
9-10 ml of whole blood for CTC extraction was obtained from 10 patients with locally 
advanced pancreatic cancer as part of an Institutional Review Board approved protocol 
(HUM00085016). 
The patients displayed an age range common for pancreatic cancer patients (53 -74 years 
of age) and were evenly distributed between males and females (Table 1). All patients 
presented with locally advanced pancreatic cancer (T4N0M0) at the beginning of the study. 
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Blood samples were taken as part of a routine visit prior to the start of the treatment. A 
second blood sample was taken from three of the patients (patient 1, 2, 4) at the end of the 
first cycle of chemotherapy. 
5.4.2 Isolation of patient-derived pancreatic circulating tumor cells 
9-10 ml of whole blood were obtained from 10 patients with locally advanced 
pancreatic cancer prior to the start of therapy and CTCs were isolated based on size using 
the continuous high throughput label free Labyrinth device (Fig 1A). The isolated CTCs 
were divided in order to: (1) enumerate CTCs (~15% of isolated CTCs) and (2) set up a 
CTC culture (~85% of isolated CTCs).Similar to previous studies188, we observed a wide 
range of CTC numbers from different patients. CTC numbers ranged from 8 cells/ml in 
patient 4 to 83 cells/ml in patient 2 (Fig 1B, Table 1).  
Since the EMT is believed to be essential for the generation of metastatic cells, we 
examined the presence of EMT-like and epithelial cells in enriched CTC samples. (Fig 1C, 
Table 1). The majority of patients (6/10) show both EMT- like and epithelial cells in the 
purified CTC samples. Nevertheless, EMT-like cells represent the majority of CTCs. Only 
EMT-like cells were observed in the remaining 4 patients. 
We were able to obtain a second blood sample from three of the patients (patient 1, 2, 4). 
This sample was taken after the first round of chemotherapy. The epithelial CTC fraction 
was lost in all three patients in response to chemotherapy, suggesting that CTCs can be 





Figure 5.1 Characterizing patient-derived pancreatic CTC’s (A) Workflow of CTC extraction, culture and subsequent analysis. (B) CTC/mL 
enumeration for 10 PDAC patients. Asterisk marks the samples that were successfully expanded. (C) Co-expression percentage of cytokeratin 
and vimentin of CTCs isolated from 10 PDAC patients and (D) two consecutive visits of 3 patients prior to treatment and after the first course 
of chemotherapy. 
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5.4.3 Circulating tumor cell culture 
Purified CTCs of all 10 patients were seeded onto fibronectin coated 24 well plates 
in order to generate CTC-derived cell lines. We were able to generate CTC-derived cell 
line from 3 individual patients (patient 1, 2 and 3). The majority of samples did not grow 
into stable CTC-derived cell lines. We observed an outgrowth of WBCs in one of the 
patients, while the remaining samples showed no growth or lost proliferation potential after 
the first passage. We did not find any correlation between stage (Table 1), CTC number 
(Fig 1B) or prior treatment with CTC growth in culture. 
The three CTC-derived cell lines display distinctly different morphologies in 
culture that are consistent with the morphology observed in pancreatic cancer cell lines 
(Fig 2A). We observed differences in growth rate that remain stable over a number of 
passages (Fig 2B). Similar to what we observed in the original CTC specimen, the cultures 
display a mixture of EMT-like and epithelial cells, which can be observed through 
differences in morphologies within cells of the same patient as well as staining for the 
respective markers (Fig 2A, C, Table 3). Patient 3 showed no presence of epithelial cells 
in the original CTC specimen. The CTC-derived cell line from this patient, however, shows 
both epithelial and EMT-like cells (Fig 1C, Fig 2C). This may be attributed to either a 
sampling related  error due to low frequency in the original specimen or to a morphological 
drift that is related to the culture conditions. 
Established CTC-derived cell lines were seeded on hanging drop array plates with 
10cells/drop in order to evaluate their ability to form spheroids (Fig 3A). All cell lines 
formed spheroids within 14 days, although we observed difference in growth rates across 
the three sample, which was similar to that of observed in the adherent cultures (Fig 2B).   
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H&E section of the spheroids show a patient-specific morphology that is consistent with 
the range of morphologies observed in pancreatic cancer (Fig 3B). Staining for the EMT 
maker vimentin and the epithelial marker cytokeratin show a mix of both populations that 
is similar to what we observed in the adherent cell lines (Fig 3C, Table 3). 
In order to verify the identity of the CTC-derived cell lines, we used STR 
fingerprinting to compare WBC and with the corresponding CTC-derived cell line. 
Additionally, we also included WBC cell line that came up during a CTC culture attempt 
in one of the patients. The WBC cell line showed a perfect match (15/15 markers) when 
compared to WBC extracted from the buffy coats of the patients archived blood sample. 
The CTC-derived cell lines, however, show very little match with their corresponding 
WBCs (patient 1: 2/15, patient 2: 1/15, patient 3: 1/15). We do observe high similarities 
between CTC cell lines of different patients (8-13/15 markers), suggesting a selection 
towards a similar phenotype.  
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Figure 5.2 Characterizing CTC-derived cell lines (A) Brightfield images 
(10x and 40x) of expanded CTC cultures. (B) Growth curve analysis of 
adherent CTC cultures (n=3). (C) Percentage of EMT-like CTC in adherent 
cultures. (D) Representative images of immunofluorescence staining using 






DAY 1 DAY 7 DAY 14 Viability H&E
Live/dead CD45/CK/DAPI
Figure 5.3 Characterizing CTC-derived spheroid cultures(A) Pancreatic CTCs were seeded on hanging drop array plates with 10 cells/drop. 
Alamarblue fluorescence was used to monitor viability/proliferation (expressed as a fold increase at Day 7 and Day 14, compared to Day 1). (B) 
Representative images of live/dead staining using calcein and ethidium homodimer at Day 14, indicate high viability within pancreatic CTC spheroids. 
(C) Representative images H&E of spheroids. (D) Immunoflourescence staining for cytokeratin (red), CD45 (green) and DAPI (blue) on spheroids. 
(Scale bar = 100µm) 
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5.4.4 Molecular Characterization of CTC PDX 
In order to investigate the whether the CTC cell lines maintain the ability to form 
tumor in vivo that maintain the morphological characteristics of pancreatic tumors, the 
CTC cell line derived from patient 3 was injected into the flanks of 4-5 week old 
NOD/SCID mice. 
We observed the appearance of tumors in all injected mice 3-4 weeks after injection 
of 106 cells (Fig 4A). Tumors were harvested when the tumor size reached the humane end 
point. At that time, we observed wide spread metastasis from the subcutaneous injection 
side to a number of organs, including liver, peritoneum and pancreas, as well as the 
development of ascites (Fig 4A, B). 
Immunohistochemistry shows cytokeratin positive subcutaneous tumors of pancreatic 
morphology that display large areas of tumor-associated stroma and invasion into the 
peritoneum (Fig 4C). 
We observed the formation of macro (Fig 4B) and micro (Fig 4D) metastasis in the 
liver. While larger tumor masses were mostly observed on the surface of liver, a high 
number of micro metastases were observed throughout the entire liver and were located 
near blood vessels. 
Pancreatic tumor masses were observed in 75% of the injected animals. Although 
some pancreatic tissue remains, the majority of the pancreas has been overtaken by tumors 
(Fig 4E). These tumors display large areas of tumor-associated stroma that are 
characteristic for the desmoplastic reaction typically observed in pancreatic cancer. 
Smad 4 staining is observed throughout the subcutaneous tumors (Fig 4F). We do however 
observe a reduction in staining intensity in areas of pleural invasion. While Smad4 staining 
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is lost in macro and micro metastases of the liver (Fig 4G), the expression is preserved in 
the pancreatic masses (Fig 4H). Similar to the subcutaneous tumors, staining intensity is 
reduced in areas of tissue invasion when compared to the tumor bulk.  
 























Figure 5.4 Characterization of the CTC PDX. (A) Injection of the CTC cell line derived 
from patient 3 into the flanks of NOD/SCID mice resulted in the development of 
subcutaneous tumors in all injected mice. Additionally, we observed wide spread 
metastases and the development of ascites. (B) Representative images of mice showing 
metastases in the liver, peritoneum, colon and pancreas. Representative images of sections 
stained for cytokeratin and H&E of (C) subcutaneous tumors, (D) liver metastases and (E) 
pancreatic metastases. Representative images of sections stained for Smad4 of (F) 
subcutaneous tumors, (G) liver metastases and (H) pancreatic metastases. 
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5.4.5 CTC cultures as a surrogate for treatment response 
The failure to predict treatment responses based on serum markers or biopsies is a 
major obstacle in the treatment of patients with pancreatic cancer. While the CTC numbers 
extracted from clinically available blood samples are too low to allow a direct analysis (Fig 
1B), a high number of cells for the analysis of treatment responses can be obtained from 
low passage cultures. 
The CTC cultures can be used for WST assays accessing proliferation in response to 
treatment as demonstrated by treatment with gemcitabine and 5FU (Fig 5A) as well as 
Flow cytometry based assays evaluating changes in cell cycle progression and 
accumulation of DNA damage in response to treatment with ionizing radiation (IR) or 
gemcitabine (Fig 5B). CTC cultures derived from patient 1 and 3 show significant 
differences in 5FU and gemcitabine sensitivity that are consistent with a previously 
untreated pancreatic cancer cell. Treatment with gemcitabine resulted in the expected 
accumulation of CTCs in s-phase, while treatment with 4Gy led to arrest in G2. 
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Figure 5.5 Treatment response of CTC cultures to chemotherapy. Response to treatment with 





Despite decades of extensive preclinical and clinical research, survival rates of 
patients with advanced pancreatic cancer have not improved significantly. The 
development of novel treatment approaches has been mostly hampered by the lack of 
available biomarkers, which can be used to access aggressiveness and metastatic potential 
and predictive/pharmacological markers of treatment response. Obtaining serial tissue 
biopsies to evaluate treatment response is not feasible in pancreatic cancer patients due to 
the invasive nature and risks associated with a biopsy. This can be overcome with CTCs, 
which can be safely obtained at any time point over the course of the treatment as part of 
routine blood draws.  
Systematic evaluation of CTC prior and during treatment will broaden our 
understanding of the biology of tumor aggression and metastasis, and ultimately improve 
treatment outcomes for pancreatic cancer patients. Beyond CTC enumeration, an ex vivo 
expansion and functional studies with in addition to the ability of screening drugs and 
evaluating patient specific therapeutic targets, patient-derived CTCs will also help to 
elucidate the presence and functional differences of small CTC subpopulations within the 
CTC pool. This can address one the critical challenges in treating pancreatic cancer; that is 
the ineffectiveness of drugs to treat the aggressive pancreatic cancer to eradicate cancer 
totally. Expanded CTCs will enable designing tailor-made treatments targeting all of the 
sub clones instead of basing decisions solely on the predominant clone. Due to low CTC 
frequency in pancreatic cancer patients, especially in early stages, expanding such cells 
becomes a dire need of any CTC functional study151. While CTC cultures have been 
reported in literature, including breast115, colon116 and lung64,success rates are low. So far, 
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no CTC cultures have been reported in pancreatic cancer.  We have previously reported 
culture of lung cancer-derived CTCs using a microfluidic co-culture device, where 14 out 
of 19 samples were expanded64. However, this approach limits the use of the cultured CTC 
for downstream applications due to non-CTC cell contaminations. To overcome these 
limitations, the study presented here used a monoculture approach of patient-derived 
pancreatic CTC isolated through the label free approach Labyrinth.  
Using the Labyrinth technology, we were able to isolate CTCs from 10 patients with 
locally advanced pancreatic cancer. The majority of the recovered cells were used to 
establish CTC cultures in vitro, while a small amount was used to evaluate and characterize 
the presence of epithelial- and EMT-like CTC sub populations.  
We were able to isolate and evaluate CTC from all patients enrolled in this study; 
however, we were only able to establish CTC lines from 3 of the patients. We observed the 
presence of both epithelial- and EMT-like populations in two  patient samples, and found 
that EMT-like cells were significantly more abundant, pointing to the aggressive nature of 
pancreatic cancer. Similar ratios of EMT to epithelial cells were also observed in the 2D 
and 3D cultures, suggesting that our culture conditions maintained the heterogeneity of the 
patient CTC population. We are, however cognizant of the fact that extended in vitro 
culture will result in the enrichment of single clones. Hence, for our experimental studies 
using CTC cultures, we restricted the usage to CTCs expanded within a maximum of 10 
passages, which allowed us to perform several functional studies. However, it is important 
to note that we are able to grow these cells with repeated thaws and freezes beyond 10 
passages. In our expanded CTCs, we observed distinct morphological differences 
associated with different phenotypes, ranging from epithelial to mesenchymal types as well 
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as significant differences in growth rate. Interestingly, we observed that CTC cell 
morphology was not predictive of molecular phenotype. For example, patient 2 exhibits 
mesenchymal-like cells with spindle like morphology (2D) and loosely packed spheroids 
(3D). However, the vimentin expression for this culture was substantially low compared to 
the other two CTC cultures. This highlights the importance of several functional studies to 
achieve a better understanding of CTCs rather than just few biomarkers by themselves.  
In an effort to verify the identity of the three CTC-derived cell lines though STR 
fingerprinting, we observed a high similarity between CTC lines. Indeed, the similarity 
between cell lines was higher that between matched pairs of CTCs and WBCs. We 
hypothesize that the adaptation for survival in the blood stream enriches for cells with 
similar pheno- and genotypes. While this observation is certainly very interesting, due to 
the low sample number we are at this time unable to draw any conclusion with respect to 
the significance of this observation.  
Previously, there are limited studies in other cancer for testing the tumor initiating 
ability of CTCs in-vivo114-116 but none in pancreatic cancer. For the first time, we were able 
to not only expand CTCs in pancreatic cancer, but also were able to demonstrate the tumor 
initiating ability of the expanded CTCs in a mouse model. Recently, a number of studies 
provided evidence for the role of CTCs in the formation of distant metastasis8,66. While 
treatment of the primary tumor is a major concern in pancreatic cancer patients that do not 
qualify for surgery, most patients succumb to the disease because of the formation of 
metastasis in liver, lung, spleen and bowel.  Consistent with the clinical phenotype of 
pancreatic cancer patients, the CTC-derived cell lines display rapid tumor growth in vivo. 
We observed wide spread metastasis in mice injected with CTC-derived cell lines that 
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match the metastatic sides that are commonly found in patients, such as liver and bowel, 
as well as the formation of ascites. These results further support the importance of CTC 
models in enhancing our understanding of the metastatic process in pancreatic cancer. 
Treatment options are very limited for pancreatic cancer patients and they typically receive 
treatment based on their tumor stage rather than using precision medicine approaches due 
to the lack of predictive markers of treatment response. We believe that CTC cultures may 
be able to fill this gap by allowing for preclinical testing of newly developed compounds 
or personalized treatment approaches in a clinical setting. We have evaluated the utility of 
two of the most commonly used methods for in vitro drug toxicity testing. Our CTC lines 
performed well in MTT cell toxicity assays and flow cytometry analysis of DNA damage 
and cell cycle progression, suggesting that these cultures can be used in range of 
cytotoxicity assays. These assays may be adapted to high throughput assays and used in 
personalized medicine approaches. Future studies will be necessary to evaluate the 
robustness of this system in a larger number of patient-derived CTC lines and evaluate the 
genetic and phenotypical stability of the cultures. 
Two consecutive samples from 3 patients were collected. These samples were 
collected prior to the start of the therapy and after the first course of chemotherapy. While 
we were not able to establish CTC lines from consecutive visits, these samples enabled us 
to evaluate changes in the CTC phenotype in response to chemotherapy. Although both 
samples contained epithelial- and EMT-like populations of CTC, we observed a trend 
towards increased numbers of EMT-like cells in response to treatment with gemcitabine. 
The small patient population enrolled in this study was not sufficient to further address this 
observation or make conclusions on the general population. Future studies in a larger 
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cohort will aim to collect multiple samples throughout the patients treatment cycle are 
currently in the planning/enrollment stage and will allow us to follow changes in the CTC 
phenotype in response to different treatment regimen. Once completed, these studies will 
shed further light on the importance of pancreatic CTCs in tumor metastasis and the impact 
of anti-cancer therapy on CTC populations. 
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CHAPTER 6. CONCLUSIONS 
 
6.1 Summary of Research Findings 
6.1.1 High-throughput Labyrinth for CTC isolation in pancreatic cancer 
A label-free microfludic device, named “Labyrinth” (Chapter 2), was developed.  
This technology is a high-throughput, continuous, and true biomarker-independent 
(without positive or negative selection) device that isolates CTCs from whole blood. The 
device facilitates the study of CTC heterogeneity by using inertial forces that lead to a size-
based isolation approach. This, in turn, enables the study of EMT-like CTCs, which are 
believed to be the most aggressive type of CTC that leads to metastasis. For applications 
in pancreatic cancer, the device was optimized at a flow rate of 2.5 mL/min, yielding both 
high CTC recovery (92%) and WBC removal (89%). Similar recoveries were achieved at 
different cell concentrations in whole blood, ranging from 10-100K cells/mL. Isolated 
CTCs were highly viable and preserved their morphology despite the high flow rate that 
the cells experienced traversing through the device. A preliminary clinical study was 
performed with 20 PDA patient samples, where CTCs were detected in all patients. CTCs 
isolated from these patients were found to contain subpopulations of CTCs expressing 
markers of both epithelial and mesenchymal-like cells. Based on these studies, the 
Labyrinth was determined to have a strong clinical application in the field of CTCs.
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6.1.2 Clinical utility of isolated CTCs using Labyrinth 
The use of CTCs for treatment monitoring was described in Chapter 3. More than 
150 patients diagnosed with pancreatic cancer were processed using the Labyrinth for CTC 
isolation and enumeration. Among this cohort, pre- and post-treatment CTC counts were 
collected from three treatment groups: (1) surgery, (2) chemotherapy, and (3) radiotherapy. 
Results showed a decrease in CTC counts for all treatment options, with statistically 
significant decreases for both chemotherapy- and radiotherapy-treated patients. The use of 
CTCs for survival predictability of pancreatic cancer patients was also studied. Results 
showed that a decrease in CTC counts correlates with higher survival probability for all 
treatment options. However, only pre-/on- chemotherapy patients had a statistically 
significant correlation. This study exhibited the potential clinical application of CTCs for 
monitoring treatment in pancreatic cancer patients. 
6.1.3 Heterogeneity among isolated CTCs  
This study utilized the Labyrinth to assess heterogeneity among pancreatic CTCs 
(Chapter 4). Patient samples were processed for CTC isolation and monitored for markers 
associated with the EMT-like and stem-cell population, including CK, CD24, and CD90. 
It was found that CK+ CTCs had CSC markers associated with them in most cases. A 
substantial number of cells collected also had multiple markers associated with CSCs. 
Lastly, tissue analysis from one patient revealed cells co-expressing CK and CD90, as well 
as CD24 and CD90. Such cells appeared to have a mixed epithelial/stromal composition. 
It is postulated that these cells have enhanced survival properties in the bloodstream and 
that they may be important for cancer progression and metastasis.  This study identified 
CTCs without the use of EpCAM and revealed unique combinations of CSC markers in 
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CTCs that could potentially be used for prognosis of and monitoring therapies for 
pancreatic cancer. 
6.1.4 In vitro and in vivo studies of CTC cultures 
In this functional study, the use of pancreatic CTC cultures as a preclinical model 
for treatment response was explored (Chapter 5).  CTCs were isolated in 10 patients with 
locally advanced pancreatic cancer using the Labyrinth and expanded in vitro for at least 
30 days using fibronectin coated plates. CTC expansion was successfully achieved in 3 of 
the samples (30% success rate). These CTC cultures were then characterized in 2D 
(adherent) and 3D (spheroid) conditions in vitro. Proliferation and epithelial/EMT features 
in both conditions were investigated and compared to the original patient specimens. 
Differences between CTC cultures for commonly used chemotherapy agents for pancreatic 
cancer therapy were also investigated. Interestingly, different patterns of drug 
susceptibility between the patient-derived CTC cultures were found. Lastly, an in vivo pilot 
study was conducted by injecting cultured CTCs into a NOD SCID mouse (n = 4), creating 
a pancreatic CDX model. To our knowledge, these are the first pancreatic CTC cultures 
developed from pancreatic patient samples. Both the expansion of CTCs and the 
heterogeneous population of cells that promote metastasis can provide meaningful 
information that can be used to elucidate the process of pancreatic tumorigenesis and 
preempt its often fatal outcome. 
6.2 Limitations and Future Directions 
6.2.1 Automation of Labyrinth in clinical setting 
The Labyrinth has been proven to have high clinical utility for CTC isolation in 
pancreatic cancer patients. Running the device is a relatively simple procedure and does 
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not require advanced technical skills. However, the Labyrinth could benefit from a 
streamlined process where sample processing is completely automated. Such a system 
could consist of a blood injection into an apparatus that would automatically perform all 
of the pre- and post-processing steps, including CTC counts. Clinical staff would just have 
to load the blood to receive automated CTC counts within a few hours. To make this 
process possible, an automatic staining and scanning procedure must be developed and 
optimized. Rocheã currently offers a system called the Discovery Ultra197. This automated 
IHC/ISH research slide staining system could be optimized for the use of ICC staining for 
isolated CTCs. The combination of this technology along with an automated CTC counter 
could streamline and automate the process of using the Labyrinth as a reliable CTC 
scanning procedure performed in a clinical setting.  
6.2.2 CTCs as an early detection tool in high risk pancreatic cancer patients  
Despite the utility of CTCs being strongly focused towards PDA patients, the 
Labyrinth could also be used for early screening of pancreatic cancer. By looking into high-
risk groups, the early stages of metastasis could be identified and an appropriate treatment 
course, in turn, could be developed to circumvent the disease. Preliminary studies 
performed with the Labyrinth suggest that such groups test positive for CTCs (Figure 6.1). 
Furthermore, these groups show greater CTC counts than healthy controls (HC) and lower 
CTC counts than PDA patients, for both epithelial and EMT-like phenotypes. These results 
indicate the potential for CTCs to be used in early screening. Future studies should focus 
on understanding the reason for this pattern as well as identifying correlations between 
CTC counts and various clinical parameters, such as disease progression, CA19-9 numbers, 
and treatment response. Furthermore, parameters within the categories classified as high-
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risk, such as pancreatic cysts, family history, and chronic pancreatitis, should also be 
investigated.   
The potential of CTCs as a biomarker for early assessment of treatment response 
for pancreatic cancer should be evaluated as a result of this study. Molecular analysis using 
PCR from the extracted genetic material of CTCs could be used to look for mutations in 
pancreatic cancer related genes, such as KRAS and p53. Such approach could assist in 
further stratification of high risk patients, including intervention and watchful waiting. This 
could also lay the groundwork for treatment decisions for targeted therapies. Future work 
could include longitudinal studies that allow disease progression monitoring during a 




6.2.3 CTC expansion  
Although 3 CTC cultures were able to be successfully expanded, the 30% success 
rate could be significantly improved. Its relatively low success rate is due to due to the lack 
of cell-to-cell interaction inherent to monoculture systems. Ideally, a protocol should be 
a. b.
Figure 6.1 Preliminary Results for CTC counts in high risk patients a. 
total CTCs/mL vs b. EMT-like CTCs 
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established to achieve a 100% success rate on CTC culture expansion. Alternative 
approaches to improve upon the discussed work could focus on identifying additional 
extracellular proteins that could provide a more nurturing microenvironment for the cells. 
For example, the Lahann laboratory has developed a synthetic polymer coating 
(PMEDSAH) that permits an undifferentiated stem cell to expand in fully defined xeno- 
free conditions over the long term (> 25 passages)198. This approach would ensure that 
CTCs under culture would not change from their original isolation phenotype. Such an 
approach would provide greater confidence when looking to answer clinical questions that 
arise from the study of CTCs. 
 Another future study would be further classification of the current CTC cultures 
into smaller CTC subpopulations. Within such subpopulations, functional studies could be 
performed to provide insight about each subgroup and their unique characteristics. For 
example, exploring what makes some CTC subpopulations more aggressive than others. 
Single-cell studies would also be a great tool to explore this question. 
6.2.4  Use of miRNA for molecular studies on expanded CTCs 
Once CTCs are successfully expanded, a plethora of functional studies could be 
performed to elucidate CTCs’ critical role in metastasis.  For example, an interesting topic 
is the use of miRNAs to investigate heterogeneity among pancreatic CTCs196. Recently, 
miRNAs have been identified as key regulators of gene expression. miRNAs are involved 
in crucial biological processes encompassing development, differentiation, apoptosis, and 
proliferation through imperfect pairing with target messenger RNAs of protein-coding 
genes and the transcriptional or posttranscriptional regulation of their expression199,200. 
Furthermore, it was shown that the miR-200 family plays a critical role in regulating EMT 
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by directly targeting the mRNA encoding genes Zeb1 and Zeb2, which are E-cadherin 
repressors201. Moreover, recent studies showed that members of the miR-200 family can 
regulate pancreatic cancer cell sensitivity to gemcitabine, which is accomplished through 
EMT induction202.  
As a proof of concept, miRNA 200 was upregulated in the established CTC cultures 
(Chapter 5) to observe phenotypic and genotypic changes related to EMT. Preliminary 
results have shown that miRNA200a can be successfully administered and transfected in 
CTC cultures. Future work involves the quantification of such miRNA200a uptake at both 
bulk and single-cell levels. For bulk studies, cultures will be examined for changes of 
epithelial and mesenchymal markers using immunofluorescence staining. Their invasion 
and migratory capability will also be studied. For single-cell level studies, CTCs will be 
microinjected with miRNA200a to show that its upregulation leads to a more epithelial 
phenotype. This study will help elucidate the clinical utility of miRNAs in understanding 
CTCs and their involvement in biological process leading to metastasis. 
6.2.5 The use of expanded CTCs for personalized therapy and drug therapies 
Failure to predict treatment responses based on serum markers or biopsies is a major 
obstacle in treating patients with pancreatic cancer. While the CTC counts extracted from 
clinically available blood samples are too low to allow for a direct analysis of treatment 
responses, a high number of cells can be obtained from low passage cultures. Therefore, it 
is hoped that expanded CTCs will serve as a potential avenue for the personalized treatment 
of pancreatic cancer. This goal could be facilitated by analyzing drug susceptibility on 
patient-derived CTCs. Several drug combinations could be tested on cultures and used as 
a guide before delivering treatment to the patient. It is hoped that, in the future, CTC 
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cultures could help identify ideal drug doses for individual patients, thus leading to more 
personalized therapies. 
6.2.6 CTCs for in vivo studies  
This study showed the potential of developing CDX models for the in vivo study of 
CTCs and their role in metastasis. While we were able to use one mice as a proof-of-
concept, future work will involve developing mouse models for the remaining two 
expanded cultures. Additionally, many functional studies could be performed to understand 
the similarities and differences between the in vitro and in vivo expanded CTCs. One 
potential aim could be the pre-selection of EMT-like CTCs to observe if they are more 
likely to metastasize faster than other CTC subgroups. Another study could focus on the 





A. Development and optimization of Labyrinth for pancreatic cancer 
 
Physics of the labyrinth  
The inertial migration based particle separation relies on the equilibrium between 
inertial lift forces and Dean flow that results in the migration of particles during laminar 
flow in microfluidic devices with curved channels. Particles in a straight channel 
experience stresses that act over the entire channel surface, including shear stress that 
yields drag forces and normal stress that yields lift forces perpendicular to the direction of 
flow. The migration of particles due to lift forces was first observed by Segré and 
Silberberg in the 1960s 137,138. Di Carlo reported that particles would be maintained at 
specific positions due to the combination of inertial lift forces where shear gradient lift 
pushes the particles toward the wall and the wall lift effect pushes the particles toward the 
center (Fig. S1a). These forces will confine the particles in a straight channel to several 
equilibrium positions, where the number of equilibrium positions is related to the geometry 
of the channel (Fig. S1c). A relation describing the magnitude of lift force (Fz) was reported 




*+,(Re,, 1,)           (1) 
where Re3 is the particle Reynolds number, Re, is the channel Reynolds number, and 1, 
is the position of the particle within the channel.The Dean flow, on the other hand, occurs 
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in the flow of curved channels. Dean flow is the secondary flow due to the centrifugal 
effects that will affect the particle equilibrium positions. Dean flow is characterized by 
counter-rotating vortices where the flow at the midline of the channel is directed outward 
around a curve, while the flow at top and bottom of the channel is directed inward (Fig. 
S1b). The drag force due to Dean flow is correlated with the particle size and curvature of 
the channel, and this drag force will also affect the equilibrium position of the particles. 
Therefore, the equilibrium between inertial lift forces and drag force from Dean flow can 
be utilized for size-based sorting.The lift forces stabilize particles at positions located along 
the centerline of a channel cross section, while Dean flow drag forces cause particles to 
circulate in the cross section (Fig. S1d). A new equilibrium position can be estimated from 







Re,=, (> < 0)             (3) 
A is the curvature ratio, A = :;*B . 
CTCs can be isolated from other blood cells in curved microfluidic devices by 
specifying an appropriate flow rate and radius of curvature. The inertial force can be 
considered as the driving force that focuses the particles, while the drag force from Dean 
flow is the force that migrates the particles away from the center of the channel, leading to 
size-based separation. For the situation where FD dominates, either particles might not be 
focused due to the insufficiency of Fz, or all the particles with different sizes could be 
pushed to the same focusing position due to the strong migration force (FD). For the case 
when Fz dominates, particles with different sizes remain at the same equilibrium positions 
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as that in a straight channel due to the dearth of migration force. A proper control of flow 
rate and good design of microfluidic structure would lead to an adequate ratio of Fz to FD 
that will cause cells to be well separated by size. 
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Hypothesis for sharp corners in Labyrinth 
 
Figure A. 1 Hypothesis for sharp corners in Labyrinth. Strong 
Dean vortices at corners would help the focusing of small particles. 
Inertial lift forces acting on smaller particles are much weaker 
compared to that on larger particles (FZ is proportional to the 4th 
power of particle size). Therefore, smaller particles (e.g. RBCs, 
WBCs) are generally difficult to focus. For instance, the large 
particles (red and blue) are easily focused thus they are already at 
the focusing position while passing through the sharp corners. The 
smaller particles (green and yellow), on the other hand, are not 
focused yet at the corner. The focusing of the green particle is 
enhanced by the strong Dean vortex at the corner and thus the green 
particle gets closer to its focusing position after passing through the 
corner. The focusing of yellow particle will be enhanced by the 
other corners in opposite direction. 
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Table A. 1 Ratio between Inertial force and Dean force  
r (m) Fz/Fd (WBCs) Fz/Fd (Cancer Cells) 
0.00225 0.405 0.81 
0.00375 0.675 1.35 
0.00525 0.945 1.89 
0.00675 1.215 2.43 
0.00825 1.485 2.97 
0.00975 1.755 3.51 
0.01125 2.025 4.05 
0.01275 2.295 4.59 
0.01425 2.565 5.13 
0.01575 2.835 5.67 
0.01725* 3.105 6.21 
0.01875 3.375 6.75 
*Currently used curvature for optimized design  
Optimization of Labyrinth configuration 
 
The optimization of the configuration in Labyrinth was based on both calculations and 
observations from experiments. As shown in following Table S1, the ratio between the 
inertial force (Fz) and Dean force (Fd), which dominates the equilibrium position of sized 
particles, were calculated in each loop for both WBCs and CTCs. Dean force is dominant 
in the inner loops (smaller r and Fz/Fd ratio), causing particles/cells focused in inner wall 
or unfocused. Lift forces are dominant in the outer loops (larger r and Fz/Fd ratio), resulting 
in the same focusing positions for both small and large particles as the condition is similar 
to straight channel. The purpose of this calculation was to find a loop which has the best 
curvature to separate CTCs from WBCs while maintaining their focusing. We also 
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observed that it takes 47 corners and 480 mm in length for WBCs to be focused, and 
therefore the design must incorporate more than this amount of corners. Combining 
experimental observations (Figure 2.1f), theoretical calculations, and numerous revisions 









Figure A. 2 Optimized design of Labyrinth b, SEM image of Labyrinth’s outlet   c, SEM 
image of corners and turns in Labyrinth Scale bar 1mm 
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CTC enrichment as a function of Labyrinth Height  
Optimization of Labyrinth and flow rate was conducted using pre-labeled MCF-7 
cell line (GFP) and WBCs (DAPI). Labyrinth with different height of microfluidic channels 
(range: 90-110 µm) were tested with spiked buffer sample at various sample flow rate 
(range: 500-3000 µL/min). In all models of Labyrinth, no streamline focusing or cell 
separation was observed at low flow rate (500-1000 µL/min), and cell focusing occurred 
at flow rate above 1500 µL/min.  
 Labyrinth with 95 µm channel height was selected as the finalized model due to its 
widest separation distance among all models. The separation is optimized at 2500 µL/min, 
where the two streamlines of cells are apart for 238 µm with a minimum gap distance of 
150 µm (as shown in Figure A.4) 
  
Figure A. 3 Legend for recorded values regarding Labyrinth height optimization 
 




Table A. 2 Streamline measurements for the Labyrinth of height 90 µm 











0.5 - - - - 
1.0 - - - - 
1.5 - 64 - - 
2.0 109 45 214 90 
2.5 73 66 252 125 
3.0 102 142 185 52 
 
Table A. 3 Streamline measurements for the Labyrinth of height 95 µm 











0.5 - - - - 
1.0 - - - - 
1.5 118 54 130 57 
2.0 140 90 159 33 
2.5 126 40 238 150 
3.0 114 142 190 73 
  
Table A. 4 Streamline measurements for the Labyrinth of height 100 µm 











0.5 - - - - 
1.0 - - - - 
1.5 168 60 219 16 
2.0 74 73 206 111 
2.5 116 47 230 118 
3.0 140 45 240 128 
 




Table A. 5 Streamline measurements for the Labyrinth of height 110 µm 











0.5 - - - - 
1.0 - - - - 
1.5 170 180 135 26 
2.0 116 49 164 73 
2.5 118 67 195 60 
3.0 95 61 197 61 
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Figure A. 4 Determination of optimal flow rate for Labyrinth. 
Higher separation between MCF-7 and WBCs streamlines projects in 
higher recovery of MCF-7 as well as higher purity. 
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Determining flow stabilization time for optimal sample recovery 
 
In order to determine the appropriate time for flow stabilization and sample 
collection, the recovery of samples was measured over time. Using pre-labeled MCF-7 cell 
line (GFP) and WBCs (DAPI), samples were processed through the Labyrinth. For each of 
the four outlets, samples were collected in individual tubes every 30-second time frame for 
90 seconds. Figure S6 shows that optimal performance is achieved within the 60-90 second 
time frame, having 93% recovery of MCF-7 and >88% WBC removal. In concordance to 
these results, our patient sample recollection analysis was only assessed for the recollected 
sample only after 1 minute.  
 
Figure A. 5 Flow stabilization measurements. a, MCF-7 breast cancer cell line and b, 
WBCs 
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Table A. 6 Comparison of microfluidic technologies with the Labyrinth 

























































NA	 NA	 NA	 NA61,114,116	 multiple	steps	 Y	 Y	 N	
CTC	chip	 Positive	selection	 1 mL/hr	 >95%	 NA	 72%	in	lung	
cancer24	
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Fabrication of SU-8 mold for Labyrinth 
The mold for the polydimethylsiloxane (PDMS) device is formed from a negative 
photoresist SU-8 100 patterned using soft lithography. Using a spin-coater, the negative 
photoresist layer, SU-8 100, is deposited onto silicon wafer rotating at 2450 rpm for 1 
minute.  The wafer is then soft-baked for 10 minutes at 65 °C and 70 minutes at 95°C.  The 
mask is aligned to the wafer and is exposed to UV light for 20 seconds.  Post-exposure-
baking is applied for 3 minutes at 65 °C and 10 minutes at 95°C. Then, the wafer is 
developed by soaking in developer for 6 minutes and in IPA for 1 minute to remove the 
inactivated photoresist. It is hard baked for 4 minutes at 150-180 °C. The height of the 
mold built on silicon wafer is 100 µm, and the width of the channel is 500 µm. 
Fabrication of PDMS device 
The flow chamber for labyrinth is made from PDMS. 30 mL Sylgard polymer base and 3 
mL curing agent are well-mixed and poured onto a silicon mold. The mixture is put in a 
desiccator for 2 hours to remove bubbles from the mixture. It is then heated at 65 °C 
overnight to harden the polymer. The polymer is cut into the desired shape, and punched 
with needle for tubing. The PDMS device is then bonded to standard sized glass slides via 
plasma surface activation of oxygen. The bonded device is tubed with 0.66 mm diameter 
tubes. 
Processing of samples using the Double Labyrinth 
Processing samples through LL involves collecting samples from second outlet and 
processing it again through a second Labyrinth device. In cell line experiments, MCF-7 
was pre-labelled with cell tracker and spiked into blood (200/mL) from healthy donors. 10 
mL of spiked blood samples was diluted to 25 mL with PBS buffer solution. The diluted 
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samples were processed through first Labyrinth at 2500 µL/min and product from second 
outlet was collected (6 mL). The collected product from first Labyrinth was processed 
through second Labyrinth at the same flow rate (2500 µL/min) and product from second 
outlet was collected as final product.  
Measuring cell viability for Labyrinth-processed cell line 
Cell viability was assessed using the MTT ((3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) colorimetric assay. In principle, MTT is taken up into cells 
by endocytosis or a protein-facilitated mechanism and is reduced by mitochondrial 
enzymes to yield a purple formazan product. The ability of cells to reduce MTT provides 
an indication of the mitochondrial integrity and activity, which, in turn, may be interpreted 
as a measure of cell viability 209. After labyrinth processing, PANC-1 cells were seeded in 
a 96 well plate for 6 days and compared with unprocessed cells (control). Data points were 
taken every 24 hours by adding 8 μL of a 5mg/mL solution of MTT powder in PBS to the 
desired well. Once violet crystals were formed, media was aspirated and 150 μL of 
isopropanol/0.1% 4mM HCL solvent was added to each well. Absorbance was measured 
at 520 nm using a Microplate reader (Bio-Tek, Winooski, VT). As shown in figure S7 cells 
started proliferating just 24 hours after being incubated, increasing their population by 50% 
within just three days. This preliminary result demonstrates that the shear stress that cells 
experience in labyrinth does not have a significant effect on their viability or their 
proliferation rates.  
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Figure A. 6 Fluorescence images of PANC-1 after Labyrinth processing 
Preparation of Cytospin slides 
Second outlet product was processed using Thermo Scientific™ Cytospin 4 
Cytocentrifuge. 300 µL of sample is added into each cytospin funnel and cytocentrifuged 
at a speed of 800 rpm for 10 minutes. Samples are fixed on the cytoslides using 4% PFA 
and cytocentrifuged at the same conditions described above. Cytoslides are stored at 4o C 
until further staining.  
Calculation of Log Depletion 
 The log depletion for single Labyrinth is calculated based on the initial number of 
WBCs spiked into the samples. After single Labyrinth, an average of 96.6% (n = 9) of 
WBCs were depleted into outlet 1, hence resulting in an average of 1.78 log depletion 
(range 1.49-2.23). The log depletion for double Labyrinth is based on the initial number of 
WBCs per mL (~0.7x10^7). The average of 350 WBCs/mL (n = 5) results in a log depletion 
of 4.3 in average (range 3.9-4.5). 
 
 
   
144 
 





Figure A. 8 Comparison between total number of CTCs/mL in pancreatic cancer. 
Total number of CTCs/mL in pancreatic cancer patients stained positive for CK19 vs total 
number of CTCs/mL in whole blood that stained positive for either epithelial (CK19) or 
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type Staining CTC/mL Stage 
P.1 Pancreatic Cancer  
CK-19 18 
Unknown ATDC 2 
ZEB1 5 
P.2 Pancreatic Cancer  
CK-19 20 
Unknown ATDC 0 
ZEB1 5 
P.3 Pancreatic Cancer  
CK-19 23 
Metastatic ATDC 0 
ZEB1 20 
P.4 Pancreatic Cancer  





P.5 Pancreatic Cancer  
CK-19 12 Borderline 
resectable ATDC 0 ZEB1 25 
P.6 Pancreatic Cancer  
CK-19 17 
Metastatic ATDC 2 
ZEB1 0 
P.7 Pancreatic Cancer  
CK-19 55 Borderline 
resectable/metastatic ATDC 12 ZEB1 30 
P.8 Pancreatic Cancer  
CK-19 12 Borderline 
resectable/metastatic ATDC 7 ZEB1 32 
P.9 Pancreatic Cancer  
CK-19 10 
Metastatic ATDC 0 
ZEB1 63 
P.10 Pancreatic Cancer  
CK-19 32 
Metastatic ATDC 0 
ZEB1 10 
P.11 Pancreatic Cancer  
CK-19 12 
Metastatic ATDC 4 
ZEB1 2 
P.12 Pancreatic Cancer  
CK-19 17 Borderline 
resectable/metastatic ATDC 10 ZEB1 19 
P.13 Pancreatic Cancer  
CK-19 33 Metastatic ZEB1 23 
P.14 Pancreatic Cancer  
CK-19 19 Locally advanced ZEB1 15 
P.15 CK-19 26 
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Pancreatic 
Cancer  ZEB1 19 
Borderline 
resectable 
P.16 Pancreatic Cancer  
CK-19 19 Metastatic ZEB1 6 
P.17 Pancreatic Cancer  
CK-19 51 Unknown ZEB1 39 
P.18 Pancreatic Cancer  
CK-19 30 Metastatic ZEB1 23 
P.19 Pancreatic Cancer  
CK-19 15 Metastatic ZEB1 19 
P.20 Pancreatic Cancer  
CK-19 4 Locally advanced ZEB1 8 
 
 
DNA isolation and mutational analysis 
DNA was extracted from five patient samples using the Acturus PicoPure DNA 
Extraction Kit. Manufacturer’s protocols were adapted for microfluidic extraction. 
Extracted DNA was concentrated using the Cleanup Protocol of the QiAmp DNA Micro 
Kit (Qiagen). All DNA samples were amplified using the REPLI-g UltraFast Mini Kit 
(Qiagen) for whole genome amplification. DNA quality and quantity were measured using 
TapeStation Genomic Tape (DNA Sequencing Core, University of Michigan). Mutations 
were detected by the ABI 7900HT (384-well Fast Block) in the 384-well format (96x4) of 
the qBiomarker Somatic Mutation PCR Array: Human Pancreatic Cancer 
(Qiagen/SABiosciences). The average Ct method was used for analysis of mutations as per 




Table A. 8 Somatic mutations in pancreatic cancer patients 
Gene/Sample C.1 C.2 C.3 C.4 C.5 HC NTC 
 
   
147 
APC WT WT WT WT WT WT WT 
BRAF WT WT WT WT WT WT WT 
CDKN2A WT WT Mutant WT WT WT WT 
CTNNB1 Mutant WT Mutant WT Mutant WT WT 
KRAS Mutant Mutant Mutant Mutant Mutant WT WT 
NRAS WT WT WT WT WT WT WT 
PIK3CA WT WT WT WT WT WT WT 
SMAD4 WT Mutant WT WT WT WT WT 
TP53 WT Mutant WT Mutant Mutant WT WT 
 
Table A. 9 Patient demographics for mutational analysis 





C.1 71 M PDA Metastatic 0 0 0 
C.2 50 M PDA Metastatic 0 11 11 
C.3 64 M PDA Borderline Resectable 3 0 3 
C.4 72 M PDA Borderline resectable 0 0 0 
C.5 61 M PDA Metastatic 0 3 3 
 
   
 
Table A. 10 Comparison of CTC counts among several microfluidic technologies 








p-MOFF Breast 24 N/A 0-21 
Portable Filter Breast  11 3.3 0.33-8 
 




Breast 5 47.4 20-67 
Vortex Chip Breast 4 N/A 3.3-6.8 
CTC-iChip Breast  12 0.93 0-3.7 
Cell Search Breast 422 11.2 0-3267 
GO-Chip Breast 10 5.6  0-16 
CTC-iChip Pancreas 6 0.59 0-1.4 
CTC-chip Pancreas 15 196±227 9-831 
Cell Search  Pancreas  8 2.7±4 0-11 
NanoVelcroCTC 
chip 
Pancreas 72  0-12 
GEDI chip  Pancreas 11 14.1±18.1 0-59 
SELEX aptamer Pancreas 14 25.7 0-126 
ISET Pancreas 60 7 1-54 
Labyrinth Breast 56 9.1 2-31 
















CTC subpopulations found on Patient Sample P.1 
 Wang et al. have identified ATDC as a protein highly expressed in the majority of 
human pancreatic adenocarcinomas and pancreatic cancer precursor lesions. They have 
also demonstrated that expression of ATDC in pancreatic cancer cells promotes cellular 
proliferation and enhanced tumor growth and metastasis. ATDC has been studied as a 
novel EMT trigger proven to be highly expressed in the majority of human PDAC. 
Moreover, our technology have been able to isolate ATDC expressing cells on P.1, in 
which colocalization with ZEB1 is observed in figure A.9. As a commonly accepted EMT 
marker, ZEB1 expression suggests that this subpopulation is of mesenchymal phenotype. 
 
Figure A. 9 CTC showing staining colocalization of ATDC and ZEB1 on P.1. 
 Scale bar 10 µm. 
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Figure A. 10 Scatter plot of CK and CD45 fluorescent intensity. 
After a patient sample was processed through Labyrinth and fluorescently stained with 
DAPI, CD45 and CK, a typical WBC from the slide was selected as reference for its CD45 
and CK fluorescent intensity levels. A cell could be recognized as a WBC by having similar 
CD45 and CK expressions comparing to the reference cell. A cell could be recognized as 
a CTC by having at least 50% lower CD45 and 50% higher CK expressions comparing to 
the reference cell. Cells with both CD45 and CK significant expressions with respect to the 
reference cell would be considered as double positive cells. Cells with DAPI positive but 
much lower expressions in CD45 and CK when compared to the reference cell would be 




































B. Enumeration of CTCs isolated from pancreatic patient samples: a clinical study 
 
Table B. 1 Median time and survival probability for treatment naive patients 




Resectable 1.875 (1.802, NA) 0.456 (0.253, 0.823) <0.001 
Borderline 2.051 (1.908, NA) 0.505 (0.312, 0.817) 
Locally Advanced  0.764 (0.498, 1.95)  0.143 (0.041, 0.493) 









C. Heterogeneity studies for the characterization of pancreatic CTCs 
 
Table C.  1 Patient Demographics 
 Stage Age Sex 
P.1 resectable T3N0M0 63 M 
P.2 resectable T3N1Mx 78 F 
P.3 resectable T3N0M0 58 F 
P.4 borderline resectable 70 M 
P.5 unresectable 62 M 
P.6 locally advanced unresectable 68 F 
P.7 locally advanced unresectable 81 M 
P.8 unresectable 52 M 
P.9 metastatic 75 M 
P.10 metastatic 66 F 
P.11 metastatic X X 
P.12 metastatic X X 
H.1 Healthy 25 M 
H.2 Healthy 26 F 












P.1 9 0 2 
P.2 8 5 0 
P.3 5 0 0 
P.4 5 3 5 
P.5 0 5 3 
P.6 16 0 0 
P.7 6 0 0 
P.8 11 8 0 
P.9 8 0 3 
P.10 3 9 0 
P.11 9 3 0 












P.1 14 7 0 
P.2 10 0 0 
P.3 10 0 0 
P.4 13 5 0 
P.5 16 3 0 
P.6 8 3 0 
P.7 21 6 0 
P.8 8 3 5 
P.9 11 0 3 
P.10 9 9 0 
P.11 15 0 0 
P.12 6 5 1 
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D. Expansion and functional characterization of pancreatic CTCs 
 
Table D. 1 Patient Demographics 








P.1*  m# 53 PDAC$ T4N0M0** 14 11 3 
P.2*  f## 74 PDAC T4N0M0 44 44 0 
P.3*  f 54 PDAC T4N0M0 20 16 4 
P.4  m 64 PDAC T4N0M0 10 6 4 
P.5*  m 53 PDAC T4N0M0 21 11 9 
P.6 f 73 PDAC T4N0M0 7 7 0 
P.7   f  60  PDAC T3N0M0  19 17 2 
P.8  f   69  PDAC  T4N0M0 49 49 0 
P.9   m  61  PDAC  T4N0M0 8 6 2 
P.10   f  50 PDAC  T4N0M0 51 45 6 
* CTC cell lines were established for these patients, # male, ## female, $ pancreatic ductal 
adenocarcinoma, **TNM classification of tumors of the exocrine pancreas: T4, tumor 
extends directly into any of the following: stomach, spleen, colon, adjacent large vessels; 
N0, no regional lymph node metastasis; M0, no distant metastasis 
 
Table D. 2 CTC number and characteristics change in response to treatment 






P.1 V1* untreated 14 11 3 
 V2 Gemcitabine, 
AZD1778 
11 9 2 
P.2 V1* untreated 44 44 0 
 V2 Gemcitabine, 
AZD1778 
3 3 0 
P.4 V1 untreated 10 6 4 
 V2 Gemcitabine, 
AZD1778 
2 2 0 
* CTC cell lines were established for these visit
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Table D. 3 CTC characteristics in CTC cultures 









P.1 87% 13% 57% 43% 
P.2 12% 88% 37% 63% 
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Figure D. 2 Six channel staining of CTC cultures 
 




Figure D. 3 Single cell analysis of CTCs from patient 3. Results from patient 3 (C-CTCs) 
compared to no cell (NC), shows the cultured cells are CTCs with 
EpCAM+/ALDH1A3+/CD44+/CD24low expression and negative for WBCs markers 
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